A REVIEW ON PHARMACOLOGICAL AND THERAPEUTIC PROPERTIES OF ECHINACEAHTML Full Text
A REVIEW ON PHARMACOLOGICAL AND THERAPEUTIC PROPERTIES OF ECHINACEA
Mostafa Ganjuri 1, Sara Darakhshan * 2, 3 and Fereidoun Taghizad 4
Department of Biology 1, Faculty of Science, Department of Physiology 4, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran.
Department of Biology 2, Faculty of Science, Razi University, Kermanshah, Iran.
Department of Pharmaceutics 3, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.
ABSTRACT: The botanical supplement market is growing at a rapid rate, and this trend is expected to continue to progress. In the world of Nutraceuticals, Echinacea plant is widely used for medicinal and commercial purposes. This Native American herb has a remarkable record of clinical and laboratory study, as well a long history of medicinal use in the management of a variety of conditions. Phytomedicinal preparations from the genus of Echinacea are widely used for the prevention and the treatment of common cold and upper respiratory tract infections. However, most of the uses of Echinacea are based on the reported immunological properties; there is a large body of evidence, based on in-vitro and animal studies, demonstrating that Echinacea possesses anti-inflammatory, anti-oxidative, and anti-microbial properties. It has also been suggested that this plant is a potential therapeutic agent for cancer, diabetes and skin problems. From the other point of view, by the available safety data, Echinacea has little adverse effects and is well tolerated. This paper reviews the pharmacological properties of the Echinacea genus and its active components.
Echinacea, Common Cold, Coneflower, Inflammation, Review
INTRODUCTION: Nowadays, the use of herbal/ botanical products has gained growing acceptance by the public due to the belief that they are natural and, therefore, safe 1. Echinacea has become a best-selling medicinal herbal preparation of all time in North America and Europe 2. Several species in the genus of Echinacea has been used for centuries, customarily as a remedy to treat a number of ailments including common cold, coughs, bronchitis, upper respiratory infections (URI), abscesses, wound infections, gangrene, eczema, dizziness, sore eyes, snake bites, syphilis, typhoid, malaria, diphtheria, hemorrhoids, and tumors 3, 4.
Numerous pharmacological investigations are available in literature, and they are related to several kinds of preparations obtained from the species of Echinacea. Interest in Echinacea is focused on its immunomodulatory effects 5-9, and particularly several clinical trials have been done in the prevention and treatment of common cold and URIs 10-14.
The beneficial effects of Echinacea are also in a variety of disease states, such as inflammation 15, 16, oxidative conditions 17, 18, cancer 19-21, skin problems 22, and liver diseases 23. Also, Echinacea exhibits anti-microbial 24-27 and antidiabetic properties 28-30. This review focuses on the pharmacological benefits of Echinacea and its active ingredients in the context of its therapeutic potentials Fig. 1. All of the relevant databases were searched for the term “Echinacea” and information on Echinacea was collected via electronic search by using PubMed and Science Direct.
FIG. 1: PHARMACOLOGICAL PROPERTIES OF ECHINACEA PLANT
Characteristics and Chemical Compounds: Echinacea, commonly called coneflower, is a genus of herbaceous perennial flowering plants in the daisy family, Asteraceae and originates in eastern North America 2. Traditional taxonomic system has reported that nine species of Echinacea exist in nature 31 Table 1, however, under a recent reclassification system, four species and eight varieties are categorized 32. Among species of the Echinacea genus, E. purpurea, E. angustifolia, and E. pallida have been the most widely used in medicine for their pharmacological properties 33 Fig. 2.
TABLE 1: SCIENTIFIC CLASSIFICATION OF ECHINACEA
|Species||Angustifolia, atrorubens, Laevigata, pallida, paradoxa, purpurea, sanguinea, simulata, tennesseensis|
FIG. 2: a) ECHINACEA PURPUREA, b) E. ANGUSTIFOLIA AND c) E. PALLIDA
The main bioactive compounds present in Echinacea species include alkylamides (alkamides), caffeic acid and its derivatives (caftaric, chlorogenic and cichoric acid, cynarin and echinacoside), polysaccharides, glycoproteins, lipoproteins, and acetylenes (polyacetylenes and polyenes) 34, 35. There are trace elements including Ca, Mg, Fe, Mn, Cu, Zn, Ni, and Li in root, stem, leaves, and flowers 36. However, the concentration of key compounds in species of Echinacea varies by plant age, plant parts used, growth conditions, geographical location, and method of extraction 37.
Also, the distribution of chemical compounds and biological activities differ within the same plant (root, stem, leaves, and flowers) 38. For example, the alkylamide content in Echinacea species appears to be higher in roots, to increase with age and to differ with the geographical area of cultivation 38.
Several forms of commercial preparations are available that use different parts of the Echinacea plant such as roots, seeds, flowers, and leaves. The most commonly used form is the tincture, which is a liquid ethanol-water extract. Other forms include powdered ethanol-water extract, freeze-dried ethanolic or hydrophilic extracts, capsule and tablet, skin cream, ointment, and gel, and pressed juice and tea.
Anti-inflammatory Effects: Currently special emphasis has been given to the role of inflammation in the pathogenesis of diseases. For a long time, medicinal plants have been used as remedies for various inflammatory conditions. The alcoholic extracts of E. angustifolia, E. purpurea, and E. pallida significantly inhibited nitric oxide (NO) production by lipopolysaccharide (LPS)-activated the RAW 264.7 macrophage cells, among which E. pallida was the most active.
The enzymes nitric oxide synthase (iNOS) and arginase metabolize a common substrate, L-arginine, but produce different biological effects. While iNOS is involved in inflammation, arginase contributes to an anti-inflammatory response. Echinacea can modulate the iNOS/arginase balance due to anti-inflammatory activation.
The alcoholic extract of E. pallida inhibited iNOS enzyme at the protein level in LPS-treated RAW 264.7 macrophages, whereas arginase activity of the cells was significantly improved by alcoholic extracts of E. angustifolia, E. pallida and E. purpurea. The hydrophilic fraction containing caffeic acid derivatives enhanced arginase activity, while the hydrophobic fraction containing alkamides inhibited iNOS expression and NO production 15. The Echinacea-mediated decrease in NO production was generally associated with a decreased protein level of iNOS, Echinacea present at the onset of LPS-induced iNOS expression led to a stronger inhibitory effect on NO production.
An alcoholic tincture of E. purpurea roots considerably inhibited the nuclear expression of pro-inflammatory transcription factors NF-κB and STATs in rhinovirus-infected cells 39. In a study using gene and protein array analysis, the effects of Echinacea commercial preparations (E1 was an aqueous expressed juice of the aerial parts of E. purpurea, and E2 was a 50% ethanol tincture from E. purpurea roots) on rhinovirus infection was evaluated by BEAS-2B, a line of human tracheobronchial epithelial cells.
It found that rhinovirus infection would increase some inflammatory cytokines at mRNA and protein levels and that these effects could be reversed by E. purpurea. Substantial increases were observed about the pro-inflammatory cytokines IL-6 and IL-8 (CXCL8) at protein levels that was ameliorated by E. purpurea 40.
E. angustifolia preparation enriched fractions Bauer alkylamide 11 and Bauer ketone 23 showed anti-inflammatory effects in LPS-induced RAW264.7 mouse macrophage cell line. These treatments decreased prostaglandin (PG)E2 production and inhibition of PGE2 production may be due to the targeting of cyclooxygenase (COX)-2 enzyme activity 41. In macrophages subjected to hydrogen peroxide (H2O2), treatment by E. angustifolia extract reversed mRNA expression of COX-2, interleukin (IL)1-β, NF-κB1, NF-κB2, and tumor necrosis factor (TNF)-α. Also peroxisome proliferator-activated receptor (PPAR)-γ to normal levels 42. In a study, 50% ethanolic tinctures of E. tennesseensis were prepared from roots, stems, leaves, and flowers of the plant. Fresh root, leaf, and flower tinctures stimulated human peripheral blood mononuclear cells (PBMC) proliferation in-vitro, also fresh root tincture stimulated IL-10 production 43. Oral administration of Echinacea alcoholic extract to mice increased production of anti-inflammatory cytokines IL-4 and IL-10 but decreased the production of TNF-α and IL-1β in activated spleen cells 44.
In murine macrophages, the alkamides significantly inhibited COX-2 activity and suppressed the LPS-induced expression of COX-2, iNOS, TNF-α, IL-1α, IL-6, and monocyte chemotactic protein (MCP)-1, but elevated heme oxygenase-1 (HO-1) protein expression 16. In RAW264.7 macrophage cells, chemically synthesized Bauer Ketones 21 and 23 from E. pallida each significantly inhibited both PGE2 and NO production, as well Bauer Alkylamide 11 repressed production of PGE2 and NO 45. Other results showed that polyunsaturated alkamides, undeca-2Z-ene-8,10-diynoic acid isobutylamide (A5), dodeca-2E-ene-8,10-diynoic acid isobutylamide (A7), and dodeca-2E,4Z-diene 8,10-diynoic acid 2-methylbutylamide (A8), isolated from roots of E. angustifolia were efficient inhibitors of COX-2 activity and suppressed PGE2 formation in H4 human neuroglioma cells 46. Ethanolic extract of E. paradoxa var. paradoxa, rich in polyenes/polyacetylenes suppressed LPS-induced production of NO, PGE2, IL-1β and IL-6 in stimulated RAW264.7 macrophage cells. Pentadeca-8Z-ene-11, 13-diyn-2-one (Bauer ketone 23) and pentadeca-8Z, 13Z-dien-11-yn- 2-one (Bauer ketone 24) from E. paradoxa were found mainly responsible for inhibitory effects on NO and PGE2 production 47.
A polysaccharide from water extract of E. purpurea roots inhibited Pam3Csk4-stimulated release of TNF-α by human THP-1 acute monocytic leukemia cells. This anti-inflammatory activity was shown to be mediated by the phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway 48. The cichoric acid from E. purpurea extract has anti-inflammatory activity in rheumatoid arthritis by collagen-induced arthritis rat model.
Administration of cichoric acid for 4 weeks significantly decreased the paw swelling, restored body weight gain, and decreased the organ index of the thymus and spleen compared with that of the arthritis group. The cichoric acid reduced the TNF-α, IL-1β and PGE-2 levels in serum; also decreased the levels of NF-κB, TNF-α and COX-2 in synovium tissues of the ankle joint compared with the arthritis group 49. A polysaccharide fraction obtained from E. angustifolia root extract (0.5 mg/kg) inhibited the carrageenan-induced rat paw edema in intravenous injection and the croton oil-induced mouse ear dermatitis when applied topically. Polysaccharidic fraction also reduced the leukocytic infiltration of the croton oil dermatitis, evaluated both from histological and peroxidase activity aspects 50. These studies suggesting that Echinacea influences inflammatory pathways and may modulate the pro/anti-inflammatory ratio.
Echinacea as an anti-oxidant: The relationship between free radicals and the incidence of various types of diseases has led to considerable interest in preventive medicine in assessing the free radical scavenging activity of medicinal plants and other nutritional anti-oxidant supplements. There have been several reports on anti-oxidative benefits of Echinacea species.
Methanolic extracts of freeze-dried E. purpurea, E. angustifolia and E. pallida roots have anti-oxidant activities and were capable of scavenging hydroxyl radical (OH·). Similar scavenging capacities for each extract were found for both 1, 1-diphenyl-2-picrylhydrazyl (DPPH) radical and ABTS radical. Moreover, all three species were found to delay the formation of conjugated diene hydroperoxide-induced by the thermal decomposition of 2, 2'-azobis (2-amidinopropane) dihydrochloride and extend the lag phase of peroxidation of soybean liposomes. Each root extract suppressed the oxidation of human low-density lipoprotein (LDL), following oxidative modification by Cu 2+ 17. The efficacy of the extracts from the stems, leaves, and roots of E. purpurea in the reaction with DPPH correlated well with the amount of cichoric acid present in the extracts. The alkamides from E. purpurea alone showed no anti-oxidant effect; however, alkamides present in the extract improved the anti-oxidative activity of cichoric acid in the peroxidation lipid emulsion 51.
In another study, the antioxidant activities of echinacoside and caffeic acid were compared by measuring their inhibition of Cu 2+- catalyzed oxidation of human LDL. The efficiency of antioxidant activity of the tested substances was: cichoric acid had the highest capacity; the second was echinacoside, and finally caffeic acid. Synergistic anti-oxidative effects of Echinacea components were found when cichoric acid (major caffeic acid derivative in E. purpurea) or echinacoside (major caffeic acid derivative in E. pallida and E. angustifolia) were combined with a mixture of alkamides and an aqueous extract containing the high molecular weight polysaccharides 52.
E. purpurea was given to mice at a dose of 30 mg/kg body weight for 14 days before and after irradiation with 3 Gy of γ-rays. The results reflected the reduced effects of γ-rays on peripheral blood hemoglobin and red blood cells, differential white blood cells and bone marrow cells counts in γ-irradiated mice. The changes observed in thiobarbituric acid-reactive substances (TBARs) level, superoxide dismutase (SOD) and glutathione peroxidase (GSPx) activities, as well DNA fragmentation were ameliorated by E. purpurea administration 18. In a study, the radio-protective properties of E. purpurea tablets in a group of radiation workers who were identified as carrying dicentric chromosomes in their lymphocytes were investigated. All radiation workers were taking two 275 mg Echinacea tablets for two-week treatment. At the end of the period, lymphocyte chromosome aberrations frequency dropped significantly, and the number of apoptotic cells increased 53.
E. purpurea administration had a suppressive effect on radiation-induced lymphocytopenia and monocytopenia and resulted in a faster recovery of blood cell counts. E. purpurea activated macrophages to stimulate IFN-γ production in association with the secondary activation of T lymphocytes, and cytokines released from macrophages in mouse peripheral blood after E. purpurea administration activated helper T cells to proliferate. Also, SOD activity in peripheral blood was increased because of echinacoside and caffeic acid as anti-oxidants which eliminate superoxide (O2_) 54. These results indicate that Echinacea and its derivatives are a good source of natural anti-oxidants and could be used to prevent the damaging effects of free radicals.
Immunomodulatory Activities: Herbal medicine provides several remedies for strengthening the body's resistance to illness by acting on various components of the immune system. A class of medicinal plants, known as immunomodulators, alters the activity of immune function through the regulation of molecules such as cytokines, chemokines, and immunoglobulins. Echinacea is a wide-spectrum immunomodulator that regulates both innate and adaptive immune responses.
In normal rats, oral administration of Echinacea preparations (containing its components cichoric acid, polysaccharides, and alkylamides) two times/day for 4 days improved phagocytic activity of alveolar macrophage, also TNF-α and NO release by the LPS-stimulated alveolar macrophages. An enhanced release of TNF-α and IFN-γ in response to Echinacea was apparent in spleen macrophages 55. In a study, extract of Echinacea aerial parts (50 mg/kg) was administered over 8 weeks to male Sprague-Dawley rats.
This treatment significantly increased circulating total white cell counts, and IL-2 level 56. Normal human peripheral blood macrophages cultured in the presence of Echinacea ethanolic extract produced higher amounts of IL-1, TNF-α, IL-6, and IL-10 than unstimulated cells. E. purpurea increased the number of cytotoxic T cells and suppressor T cells. An increase was observed in IFN-γ levels which activated cell-mediated immune responses, such as proliferation and activation of type I helper T (Th1) cells 57.
Sullivan et al., examined the effects of polysaccharides isolated from E. purpurea on macrophages. Murine peritoneal macrophages were cultured with E. purpurea extract enriched for polysaccharide. The results showed an E. purpurea extract stimulated production of IL-6, IL-12, and NO from macrophages.
E. purpurea triggered a signaling cascade within macrophages through both TLR4-dependent and -independent mechanisms, involving ERK, p38 and c-Jun N-terminal kinase (JNK), and ultimately the activation of NF-κB 58. E. purpurea whole herb and root powders were found to stimulate murine macrophage for TNF-α, IL-1α, IL-1β, IL-6, IL-10, and NO secretion, as well as to enhance the viability significantly and proliferation of human peripheral blood mononuclear cells (PBMCs) in-vitro 59.
Randolph et al. in a preliminary study in six healthy individuals found that in-vitro exposure of THP-1 peripheral leukocytes to Echinacea extract induced expression of the IL-1α, IL-1β, IL-8, TNF-α, intracellular adhesion molecule (ICAM), and IL-10 genes. Serum and hematological values were not different from baseline, suggesting that liver or bone marrow responses were not involved in acute responses to Echinacea 60. Echinaforce® is the standardized E. purpurea preparation from the combined root and aerial ethanolic extract, from Bioforce, Switzerland. In an ex-vivo study oral administration, Echinaforce® reduced the pro-inflammatory mediators TNF-α and IL-1β, and increased anti-inflammatory IL-10 levels.
Chemokines macrophage inflammatory protein-1 (MIP-1)α and IL-8 were up-regulated in blood samples from subjects treated with Echinaforce® 61. Polinacea® is a standardized hydroethanolic extract obtained from E. angustifolia roots containing echinacoside, the high molecular weight polysaccharide IDN 5405 and an isobutylamide fraction. Polinacea® in 10 healthy subjects was administered as herbal syrup once a day for 30 days (containing 100 mg). Results showed the up-regulation of mRNA expression of IL-2 and IL-8 and the down-regulation mRNA levels of the pro-inflammatory cytokines TNF-α and IL-6; these changes positively correlated with the protein levels detected in the plasma 62. E. purpurea ethanolic extract can regulate the differentiation of dendritic cells (DCs), which are known as professional antigen-presenting cells. Alkylamide-rich root extract similarly promoted maturation of human DCs as LPS; however, the stem plus leaf extract inhibited DC maturation. Down-regulation the mRNA expression of chemokines MIP-1α, and MCP-2, and receptors CD191 (CCR1) and CDw199 (CCR9) were observed in stem plus leaf extract-treated DCs.
Regulatory molecules MIP-1β and MCP-1 involved in the c-Jun pathway were found to be up-regulated in root extract-treated DCs 5. The polysaccharide-rich root extract of E. purpurea increased the expression of MHC class II, CD86, and CD54 surface biomarkers after 48 h of exposure, whereas the alkylamide-rich leaf extract inhibited the expression of these molecules. Production of IL-6 and TNF-α increased with exposure to the root; in contrast, the leaf extract inhibited COX-2 activity. While both extracts decreased the uptake of ovalbumin by murine bone marrow-derived dendritic cells (BMDCs), the leaf extract inhibited the antigen-specific activation of naïve CD4+ T cells from OT II/Thy1.1 mice 7.
Echinacea is found to be a potent activator of natural killer (NK) cells; these cells are active in non-specific immunity against virus-mediated infections and tumors. Mice immunized with sheep red blood cells (sRBC) were gavaged for 7 days with each of the alcohol extracts from E. angustifolia, E. pallida, and E. purpurea. The three extracts increased percentages of CD49+ and CD19+ lymphocytes in spleen and NK cell cytotoxicity.
Antibody response to sRBC was improved equally by extracts of all three Echinacea species. Also, each extract significantly increased IFN-γ production but inhibited the release of TNF-α and IL-1β. E. angustifolia- and E. pallida-treated mice demonstrated higher production of IL-4 and increased IL-10 production 44. E. purpurea may be capable of stimulating non-specific immunity in the elderly.
E. purpurea after two weeks of administration could increase the number of NK cells in aging mice, reflecting increased new NK cell production in their bone marrow generation site, leading to an increase in the absolute numbers of NK cells in the spleen, their primary origin 63.
Administering root extract of E. purpurea daily for 50 days from the onset of leukemia in mice augmented NK cells and prolonged life span. Treatment had an increasing effect on the absolute numbers of NK cells in spleens in 9 days (intermediate stage leukemia). Three months after leukemia beginning, E. purpurea-treated leukemic mice had 2-3 times the normal numbers of NK cells in their spleens, also all the major hemopoietic and immune cell lineages in their bone marrow origin site were recorded at normal numbers 64.
Echinacea increased the frequency of NK target conjugates and activated the programming for lysis of NK cells. Echinacea resulted in the activation of CD69 expression and an increase in mean fluorescence intensity in both the CD16+ and CD56+ NK subsets. As well, the frequency of CD56+ killer cells in the conjugates was also significantly increased by Echinacea. There was the recruitment of non-conjugated CD56+ cells into CD16+ NK-target conjugates and activation of the NK-target non-killer conjugates into killer cells 65.
Water-soluble extract from E. purpurea fresh aerial parts (containing 80% polysaccharides, phenolic compounds, cynarin, cichoric and caftaric acids) strongly enhanced T-cell production of IL-2 and IFN-γ in response to phorbol 12-myristate 13-acetate (PMA) plus ionomycin stimulation 66. The addition of cichoric acid from a root extract (prepared from both E. angustifolia and E. purpurea) and 2,4-diene alkylamide-derived from combination of both species induced NF-κB expression after PMA stimulation of Jurkat T-cell line 67.
In a study by Sasagawa et al., Jurkat cells were treated with ethanolic extract prepared from dried leaves and flowers of Echinacea with alkylamides or caffeic acid derivatives. E. purpurea 95:5 ethanol/water extract inhibited phytohemagglutinin in-dependent production of IL-2, and this inhibitory activity correlated with the presence of alkylamides but not caffeic acid derivatives 9.
A mixture of E. purpurea and Glycyrrhiza glabra root (Revitonil® tablets) showed a stimulatory effect on human granulocytes, and notable stimulating activity was observed in the T-lymphocyte CD69 bioassay 68. It found that decreased number and function of regulatory T cells (Tregs) in association with the enhanced feeder function of antigen-presenting cells (APCs) may contribute to the improvement of immune function by E. purpurea.
The CD4+ FoxP3+ and CD4+CD25+ Tregs incidence were attenuated, and CD4+CD25+ Tregs function was decreased, while the feeder function of APCs was enhanced in the mice spleens administered with E. purpurea for 3 weeks 69.
Echinacea has the potential for enhancement of humoral immune responses as well as innate immunity. An alcohol extract of Echinacea improved the T cell-dependent antibody response to immunization with sRBCs in mice and increased splenic T cell production of IL-4 and IL-10 suggesting that Echinacea stimulation of both Th-2 and Th-1 cytokine production improved B cell function and increased antibody formation 44. A diet supplemented with 1% w/w Echinacea for 28 days can enhance immune function by increasing antibody production which resulted from augmenting both Th1 and Th2 cytokine production. Production amount of IgA, IgG, and IgM was higher in the splenic lymphocytes of rats fed with Echinacea 70.
Arabinogalactan-proteins (AGPs) purified from roots of E. pallida, and suspension culture of E. purpurea induced the IgM-production of mouse lymphocytes and stimulated IL6-production in alveolar mouse macrophage culture 71. A study by Rehman and colleagues 6 demonstrated that oral administration E. angustifolia root extract of rats for 6 weeks which were injected with the antigen keyhole limpet hemocyanin (KLH) and re-exposed to KLH after the initial exposure, showed a significant augmentation of their primary and secondary IgG response to the antigen 6. Extract of E. purpurea enhanced cellular immune function of PBMC both from normal individuals and patients with either the chronic fatigue syndrome or the acquired immunodeficiency syndrome (AIDS). The addition of herb significantly increased both antibody-dependent and NK-mediated activities against cells infected with herpesvirus 72.
Polysaccharides isolated from E. purpurea activated peritoneal macrophages after administration of cyclophosphamide or cyclosporine A (CsA) in immunodeficient mice. E. purpurea-treated macrophages exhibited increased production of TNF-α and higher cytotoxicity against tumor target WEHI-164 as well as against the intracellular Leishmania enrietti. After a cyclophosphamide-mediated reduction of leukocytes in the peripheral blood, the polysaccharides induced an earlier influx of neutrophil granulocytes.
E. purpurea treatment after cyclophosphamide or CsA restored their resistance against lethal infections with the macrophage-dependent pathogen Listeria monocytogenes and predominantly granulocyte-dependent Candida albicans 73. Polinacea® administered orally showed an immune-stimulating activity by reducing the C. albicans-induced mortality both in normal and in CsA-treated mice. It enhanced T-cell function and proliferation by stimulating IFN-γ production in anti-CD3-treated murine T-cell cultures 74.
Echinacea-derived alkamides have a structural similarity to anandamide, an endogenous ligand of cannabinoid receptors; consequently, it was found that alkamides bind to cannabinoid receptor (CB) type-1 and -2, therefore suggested as a new class of cannabinomimetics 75. The CB2 receptor is abundantly expressed in some of the inflammatory and immune cells, and there is evidence that the CB2 receptor plays a role in inflammatory also immune responses, as well as related pathophysiological conditions 76.
N-alkylamides from E. purpurea and E. angustifolia preparations are capable of stimulating IL-10 and inhibiting expression of TNF-α protein. N-alkylamides exerted pleiotropic effects modulating the endocannabinoid system by activating the CB2 receptor, endocannabinoid transport and degradation 77. Alkylamides dodeca-2E, 4E, 8Z, 10E/Z-tetraenoic acid isobutylamides (1/2), trienoic (3) and dienoic acid (4) derivatives induced synthesis of TNF-α mRNA in primary human monocytes/macrophages. This up-regulation was found to be mediated by CB2 receptors, increased cAMP, p38/MAPK and JNK signaling, as well as NF-κB and ATF-2/CREB-1 activation 78. Also E. purpurea stimulated prolactin secretion in rats 79, and it has been described that prolactin plays a significant role in immune system regulation.
A controversy result showed that cynarin isolated from E. purpurea down-regulated immune responses by binding to CD28, a receptor of T-cells on T-lymphocytes, and this interaction is stronger than the binding between CD28 and CD80, a co-stimulated receptor of antigen presenting cells. Cynarin's function was proved by its ability to down-regulate CD28-dependent IL-2 expression in a T-cell culture line 80. It is believed that the immunomodulatory effects of Echinacea depend on the combined action of alkamides, polysaccharides, and chicoric acid.
These components are potentially effective in stimulating humoral immunity as well as innate immune responses. It appears likely that Echinacea stimulates the immune system via multiple pathways. Echinacea can affect non-specific immune response, activate innate immune cells such as macrophages, polymorphonuclear leukocytes, and NK cells, stimulate phagocytosis, and inhibit the production of inflammatory mediators by white blood cells.
The results about Echinacea immunomodulation seem inconclusive and controversial; some studies express that Echinacea is an immunostimulatory and some of them state it is an immune suppressor. It is noteworthy to mention that immunity is a two-edged blade that the body keeps under tight control; excessively strong immune reactions can be precarious. Based on this concern, Echinacea should be used with caution by individuals with autoimmune disorders such as rheumatoid arthritis and multiple sclerosis. On the other side, Echinacea can stimulate immunity and may be harmful where immunosuppression could be vital in some people such as in organ transplantation. Further studies are needed to clarify the mechanisms which are responsible for the beneficial effect of Echinacea observed in the immune system.
Anti-Cancer Effects: Interest in herbal medicine for cancer therapy has dramatically grown over the past years. Cancer patients may wish to use natural botanicals to inhibit tumor growth and development. Echinacea and its compounds have shown promising anti-tumor effects. The hexanic root extract of the E. purpurea, E. angustifolia and E. pallida reduced cell viability in human pancreatic MIA PaCa-2 and colonic COLO320 cancer cell lines in a concentration- and time-dependent manner. E. pallida extract induced apoptosis by increasing caspase-3 activity and the internucleosomal degradation of DNA, without evidence of necrotic cell death 81. Five compounds, two polyacetylenes (namely, 8-hydroxy-pentadeca-(9E)-ene-11,13-diyn-2-one and pentadeca-(9E)-ene- 11,13-diyne-2,8-dione) and three polyenes (namely, 8-hydroxy-pentadeca-(9E,13Z)-dien-11-yn-2-one, pentadeca- (9E,13Z)-dien-11-yne-2,8-dione and pentadeca-(8Z,13Z)-dien-11-yn-2-one) isolated from the n-hexane extract of E. pallida roots induced apoptosis in pancreatic MIA PaCa-2 and colonic COLO320 cancer cells 82.
Ethanolic extract of E. purpurea flowers and its major compound cichoric acid showed a significant inhibitory effect on the proliferation of human colon cancer cells Caco-2 and HCT-116 in a dose- and time-dependent manner. Cichoric acid was able to decrease telomerase activity in HCT-116 cells. Moreover, cichoric acid effectively induced apoptosis in colon cancer cells, which were characterized by DNA fragmentation, activation of caspase-9, cleavage of poly-ADP-ribose polymerase (PARP) and down-regulation of β-catenin 19.
An acetylenic constituent of E. pallida roots, namely pentadeca-(8 Z,13 Z)-dien-11-yn-2-one, revealed a concentration-dependent cytotoxicity on leukemia Jurkat and HL-60, breast carcinoma MCF-7, and melanoma MeWo cell lines. This component arrested the cell cycle in the G1 phase on HL-60 cells 20. When a commercially extract of E. purpurea root was administered to mice immunized with killed leukemia cells in an erythroleukemic mouse model for 3 months the number of NK cells was elevated compared to animals without receiving the Echinacea.
In the group fed with Echinacea product in the early phase of the tumor development the number of T- and B lymphocytes in the spleen was markedly enhanced 21. E. purpurea had suppressive effects on spontaneously occurring leukemia caused by endogenous recombinant murine leukemia viruses (MuLV).
Female AKR/J mice were given oral 7.5 mg/week dose of E. purpurea leaves powder for 8 weeks. Mortality from thymic lymphoma was delayed, and enlargement of thymic lymphoma in experimental mice was suppressed with E. purpurea preparation. The proliferation of MuLV in the thymus was markedly inhibited after oral administration of the E. purpurea. Production of endogenous IFN-γ in mice was also effectively augmented by the oral treatment with herb 83. The administration of 50 mg/kg E. purpurea extract to rats with benign prostate hyperplasia (BPH) for 4 and 8 weeks gradually and considerably reduced the prostate mass and reversed the degenerative changes in the structure of the prostate 84.
Gastrointestinal mucositis is a common complication of chemotherapeutic drugs, and there is currently no effective long-term treatment. SAMITAL® is an oral suspension formulation based on the combination of three standardized extracts from Vaccinium myrtillus, Macleaya cordata fruits and E. angustifolia roots designed for the relief of oral mucositis induced by chemotherapy and/or radiotherapy in cancer patients. 20 pediatric patients undergoing chemotherapy initially received oral SAMITAL® to treat gastrointestinal mucositis and were then given SAMITAL® prophylactically to prevent recurrences with successive cycles of chemotherapy. SAMITAL® significantly decreased gastrointestinal mucositis grade, reduced pain, mucosal erosions, bleeding and dysphagia 85. Phase II trials with SAMITAL® as part of an overall clinical development program are currently ongoing 86.
These results represent scientific evidence on the possible role of Echinacea species in medical oncology. Because the agents used for cancer chemotherapy are known to be highly toxic towards normal cells, immune-enhancing activities by Echinacea is looked into with interest and more research is needed in this area.
Anti-Microbial Properties: Several anti-microbial agents are available but have some side effects. To overcome this problem, many natural sources particularly medicinal plants can be considered as alternatives.
E. pallida and E. purpurea inhibited NO production and TNF-α release from LPS-stimulated RAW 264.7 macrophage cells in response to infection of Salmonella enterica. Upon bacterial infection, RAW 264.7 cells produced high levels of NO; however, an alcoholic extract of Echinacea administered orally for one week decreased NO production in a dose-dependent manner 87.
The use of E. purpurea extract had a prophylactic effect on the development of Pseudomonas aeruginosa infection. E. purpurea feeding resulted in diminishing bacterial number in livers of C57Bl/6 (susceptible strain) and B6C3F1 (relative resistant strain) mice. Echinacea feeding of the second relative resistant strain (BALB/cx C3H) F1 resulted in stimulation of granulocytes chemiluminescent and lymphocytes proliferative response 88.
Echinacea could inactivate certain respiratory bacteria and could also reverse the inflammatory effects caused by these bacteria in epithelial cells. Echinaforce® inactivated Streptococcus pyogenes (Group A streptococcus), which is often associated with sore throat and more severe pulmonary infections. Hemophilus influenza and Legionella pneumophila were also readily inactivated, and their cellular pro-inflammatory response completely reversed.
Moreover, Staphylococcus aureus (methicillin-resistant and sensitive strains) and Mycobacterium smegmatis were also sensitive to Echinaforce®24 Influenza infection is an important clinical problem. Echinacea extracts and active components have the potential for being used in improving the pathology of influenza infections. Echinaforce® has potent antiviral activity against the IV strains, human Victoria (H3N2) and PR8 (H1N1), avian strains KAN-1 (H5N1) and FPV (H7N7), and the pandemic S-OIV (H1N1). Human H1N1-type IV, highly pathogenic avian IV (HPAIV) of the H5 and H7 types, as well as swine-origin IV (H1N1), were inactivated in treatment by Echinaforce®. Hemagglutination assays showed that Echinaforce® inhibited the receptor binding activity of the virus, suggesting that the extract restricted the viral entry into cells.
In sequential passage studies under in-vitro treatment with the H5N1 virus, no Echinaforce®-resistant variants appeared, in contrast to Tamiflu, which produced resistant viruses upon passaging. Also, the Tamiflu-resistant viruses were susceptible to Echinaforce® as well as the wild type viruses 26.
The alkyl amides undeca-2Z,4E-diene-8,10-diynic acid isobutylamide, dodeca-2E,4E,8Z, 10E/Z tetraenoic acid isobutylamide, dodeca-2E,4E-dienoic acid isobutylamide, and undeca-2E-ene-8,10-diynoic acid isobutylamide suppressed production of TNF-α and PGE2 from RAW 264.7 macrophage cells-infected with H1N1 influenza. A strain PR/8/34. Dodeca-2E, 4E-dienoic acid isobutylamide especially inhibited production of these mediators and also strongly suppressed production of granulocyte-colony stimulating factor (G-CSF), MCP-1, MIP-1α and CCL5 (RANTES) 89. In the context of influenza virus-stimulated human PBMCs from older individuals vaccinated against influenza, E. tennesseensis root tinctures augmented IL-10 production, diminished IL-2 production, and had no effect on IFN-γ production 90.
Results indicated that rhinovirus infection of epithelial cells treated with Echinacea led to profound effects on numerous mediators. An alcohol tincture from E. purpurea roots increased the expression of several transcription factors in a non-activated human bronchial epithelial BEAS-2B cell line but inhibited the expression of these when the cells were infected with rhinovirus. The BEAS-2B cells were used as the model, and nuclear extracts of uninfected cells and rhinovirus-14 infected cells were examined with and without treatment with E. purpurea extract. It was found that Echinacea increased the nuclear content of several transcription factors, including pro-inflammatory factors such as activator protein (AP)-1, AP-2, NF-κB, and STATs 1-6. Infection by rhinovirus resulted in a more dramatic increase in these transcription factors; however, when rhinovirus-infected cells were treated with Echinacea, transcription factor levels were reduced to low levels 39. Preparations include juice from the aerial parts of the plant (which contain polysaccharides) and alcoholic tinctures from roots (containing caffeic acid derivatives and alkylamides) stimulated the release of pro-inflammatory factors from uninfected BEAS-2B bronchial epithelial cells. Exposure to Rhinovirus 14 stimulated the release of several chemokines known to attract inflammatory cells, and most these effects were reversed by introduction either of the two Echinacea extracts 91. These results could explain the anti-inflammatory effects of Echinacea.
The rhinovirus type 1A (RV1A) resulted in increased mucopolysaccharide inclusions in the goblet cells of normal human airway epithelial cells; this change was reversed by Echinacea treatment. Echinacea could ameliorate mucus production during colds because mucin secretion stimulated by RV1A is reversed by Echinacea treatment. Echinacea also inhibited secretion of substantial amounts of the pro-inflammatory cytokines IL-6 and IL-8 in RV-infected tissues 92.
The hydroalcoholic extract also pressed juice of E. pallida exhibited anti-viral activity against herpes simplex virus types 1 and 2 (HSV-1, HSV-2) in a dose-dependent manner. Plaque formation was significantly reduced by more than 99% or completely absent. Also, Echinacea juice revealed anti-viral activity during all phases of the viral replication cycle, protected cells against viral infection by interfering with virus attachment and could interact with herpes virus inside and outside the cell 93.
A polysaccharide isolated from E. purpurea promoted immune response, leading to a reduced latency phase, and it has a promising effect on latency prevention in HSV-1 when supplied before infection 94. The rhinoviruses 1A and 14, influenza virus, respiratory syncytial virus (RSV), adenovirus types 3 and 11, and HSV-1 induced secretion of IL-6 and IL-8, in addition to several other chemokines, depending on the virus; and Echinaforce® inhibited this induction.
E. purpurea preparation effectively inhibited the virus-induced cytokine secretion and pro-inflammatory responses induced by all the viruses tested in BEAS-2B human bronchial epithelial cells. This preparation also showed potent virucidal activity against viruses with membranes such as RSV, HSV, and influenza virus, at the oral recommended dose 95.
In an open-label, fixed-sequence study, 50 patients infected by human immunodeficiency virus (HIV) received anti-retroviral therapy including 400 mg etravirine (a non-nucleoside reverse transcriptase inhibitor of HIV) once daily for 4 weeks. Capsules containing E. purpurea root extract were added to the anti-retroviral treatment (500 mg every 8 h) for two weeks.
Results showed that the coadministration of E. purpurea with etravirine was safe and well tolerated in HIV-infected patients 96. Cichoric acid has been shown to inhibit the HIV-type 1 integrase, improved the anti-HIV-1 effect of Zidovudine and protease inhibitor (AG1350) in-vitro 97.
Echinaforce® inhibited the growth of three species of trypanosomatids: Leishmania donovani, Leishmania major, and Trypanosoma brucei. L. donovani stimulated the production of the pro-inflammatory IL-6 and IL-8 cytokines in human bronchial epithelial cells and skin fibroblasts, but Echinaforce® eradicated this stimulation by anti-inflammatory effect 98. By application of purified polysaccharides from cell cultures of E. purpurea, peritoneal macrophages killed cells infected either with the parasite Leishmania enriettii, or with yeast Candida albicans 99.
Extracts from Echinacea inhibited the growth of several yeasts such as Saccharomyces cerevisiae, Candida shehata, C. kefyr, C. albicans, C. steatulytica and C. Tropicalis 25. The alkamides from Echinacea acted synergistically to disrupt the fungal cell wall and cell membrane, a target for specific inhibition of fungal pathogens. S. cerevisiae cells exposed to sub-inhibitory concentrations of synthetic alkamides and Echinacea extract exhibit increased frequencies of cell wall damage and death, which were comparable to caspofungin and significantly greater than hygromycin and nourseothricin, which inhibit protein synthesis 100.
These results provide evidence that bacterial, viral, and fungal infections could be halted by Echinacea administration.
Anti-Cancer Effects: Interest in herbal medicine for cancer therapy has dramatically grown over the past years. Cancer patients may wish to use natural botanicals to inhibit tumor growth and development. Echinacea and its compounds have shown promising anti-tumor effects.
The hexanic root extract of the E. purpurea, E. angustifolia, and E. pallida reduced cell viability in human pancreatic MIA PaCa-2 and colonic COLO320 cancer cell lines in a concentration- and time-dependent manner. E. pallida extract induced apoptosis by increasing caspase-3 activity and the internucleosomal degradation of DNA, without evidence of necrotic cell death 81.
Five compounds, two polyacetylenes (namely, 8-hydroxy-pentadeca-(9E)-ene-11,13-diyn-2-one and pentadeca-(9E)-ene- 11,13-diyne-2,8-dione) and three polyenes (namely, 8-hydroxy-pentadeca-(9E,13Z)-dien-11-yn-2-one, pentadeca- (9E,13Z)-dien-11-yne-2,8-dione and pentadeca-(8Z,13Z)-dien-11-yn-2-one) isolated from the n-hexane extract of E. pallida roots induced apoptosis in pancreatic MIA PaCa-2 and colonic COLO320 cancer cells 82.
Ethanolic extract of E. purpurea flowers and its major compound cichoric acid showed a significant inhibitory effect on the proliferation of human colon cancer cells Caco-2 and HCT-116 in a dose- and time-dependent manner. Cichoric acid was able to decrease telomerase activity in HCT-116 cells. Moreover, cichoric acid effectively induced apoptosis in colon cancer cells, which were characterized by DNA fragmentation, activation of caspase-9, cleavage of poly-ADP-ribose polymerase (PARP) and down-regulation of β-catenin 19.
An acetylenic constituent of E. pallida roots, namely pentadeca-(8 Z,13 Z)-dien-11-yn-2-one, revealed concentration-dependent cytotoxicity on leukemia Jurkat and HL-60, breast carcinoma MCF-7, and melanoma MeWo cell lines. This component arrested the cell cycle in the G1 phase on HL-60 cells 20. When a commercially extract of E. purpurea root was administered to mice immunized with killed leukemia cells in an erythroleukemic mouse model for 3 months the number of NK cells was elevated compared to animals without receiving the Echinacea.
In the group fed with Echinacea product in the early phase of the tumor development the number of T- and B lymphocytes in the spleen was markedly enhanced 21. E. purpurea had suppressive effects on spontaneously occurring leukemia caused by endogenous recombinant murine leukemia viruses (MuLV). Female AKR/J mice were given oral 7.5 mg/week dose of E. purpurea leaves powder for 8 weeks.
Mortality from thymic lymphoma was delayed, and enlargement of thymic lymphoma in experimental mice was suppressed with E. purpurea preparation. The proliferation of MuLV in the thymus was markedly inhibited after oral administration of the E. purpurea. Production of endogenous IFN-γ in mice was also effectively augmented by the oral treatment with herb 83.
The administration of 50 mg/kg E. purpurea extract to rats with benign prostate hyperplasia (BPH) for 4 and 8 weeks gradually and considerably reduced the prostate mass and reversed the degenerative changes in the structure of the prostate 84.
Gastrointestinal mucositis is a common complication of chemotherapeutic drugs, and there is currently no effective long-term treatment. SAMITAL® is an oral suspension formulation based on the combination of three standardized extracts from Vaccinium myrtillus, Macleaya cordata fruits and E. angustifolia roots designed for the relief of oral mucositis induced by chemotherapy and radiotherapy in cancer patients. 20 pediatric patients undergoing chemotherapy initially received oral SAMITAL® to treat gastrointestinal mucositis and were then given SAMITAL® prophylactically to prevent recurrences with successive cycles of chemotherapy. SAMITAL® significantly decreased gastrointestinal mucositis grade, reduced pain, mucosal erosions, bleeding, and dysphagia.85 Phase II trials with SAMITAL® as part of an overall clinical development program are currently ongoing 86. These results represent scientific evidence on the possible role of Echinacea species in medical oncology. Because the agents used for cancer chemotherapy are known to be highly toxic towards normal cells, immune-enhancing activities by Echinacea is looked into with interest and more research is needed in this area.
Anti-Microbial Properties: Several anti-microbial agents are available but have some side effects. To overcome this problem, many natural sources particularly medicinal plants can be considered as alternatives. E. pallida and E. purpurea inhibited NO production and TNF-α release from LPS-stimulated RAW 264.7 macrophage cells in response to infection of Salmonella enterica. Upon bacterial infection, RAW 264.7 cells produced high levels of NO; however, an alcoholic extract of Echinacea administered orally for one week decreased NO production in a dose-dependent manner 87. The use of E. purpurea extract had a prophylactic effect on the development of Pseudomonas aeruginosa infection.
E. purpurea feeding resulted in diminishing bacterial number in livers of C57Bl/6 (susceptible strain) and B6C3F1 (relative resistant strain) mice. Echinacea feeding of the second relative resistant strain (BALB/cx C3H) F1 resulted in stimulation of granulocytes chemiluminescent and lymphocytes proliferative response 88.
Echinacea could inactivate certain respiratory bacteria and could also reverse the inflammatory effects caused by these bacteria in epithelial cells. Echinaforce® inactivated Streptococcus pyogenes (Group A streptococcus), which is often associated with sore throat and more severe pulmonary infections. Hemophilus influenza and Legionella pneumophila were also readily inactivated, and their cellular pro-inflammatory response completely reversed. Moreover, Staphylococcus aureus (methicillin-resistant and sensitive strains) and Mycobacterium smegmatis were also sensitive to Echinaforce® 24 Influenza infection is a significant clinical problem.
Echinacea extracts and active components have the potential for being used in improving the pathology of influenza infections. Echinaforce® has potent antiviral activity against the IV strains, human Victoria (H3N2) and PR8 (H1N1), avian strains KAN-1 (H5N1) and FPV (H7N7), and the pandemic S-OIV (H1N1). Human H1N1-type IV, highly pathogenic avian IV (HPAIV) of the H5 and H7 types, as well as swine-origin IV (H1N1), were inactivated in treatment by Echinaforce®. Hemagglutination assays showed that Echinaforce® inhibited the receptor binding activity of the virus, suggesting that the extract restricted the viral entry into cells.
In sequential passage studies under in vitro treatment with the H5N1 virus no Echinaforce®- resistant variants appeared, in contrast to Tamiflu, which produced resistant viruses upon passaging. Also, the Tamiflu-resistant viruses were susceptible to Echinaforce® as well as the wild type viruses 26.
The alkyl amides undeca-2Z,4E-diene-8,10-diynic acid isobutylamide, dodeca-2E,4E,8Z,10E/Z tetraenoic acid isobutylamide, dodeca-2E,4E-dienoic acid isobutylamide, and undeca-2E-ene-8,10-diynoic acid isobutylamide suppressed production of TNF-α and PGE2 from RAW 264.7 macrophage cells-infected with the H1N1 influenza A strain PR/8/34.
Dodeca-2E, 4E-dienoic acid isobutylamide especially inhibited production of these mediators and also actively suppressed production of granulocyte-colony stimulating factor (G-CSF), MCP-1, MIP-1α and CCL5 (RANTES) 89. In the context of influenza virus-stimulated human PBMCs from older individuals vaccinated against influenza, E. tennesseensis root tinctures augmented IL-10 production, diminished IL-2 production, and had no effect on IFN-γ production 90. Results indicated that rhinovirus infection of epithelial cells treated with Echinacea led to profound effects on numerous mediators.
An alcohol tincture from E. purpurea roots increased the expression of several transcription factors in a non-activated human bronchial epithelial BEAS-2B cell line but inhibited the expression of these when the cells were infected with rhinovirus. The BEAS-2B cells were used as the model, and nuclear extracts of uninfected cells and rhinovirus-14 infected cells were examined with and without treatment with E. purpurea extract. It was found that Echinacea increased the nuclear content of several transcription factors, including pro-inflammatory factors such as activator protein (AP)-1, AP-2, NF-κB, and STATs 1-6. Infection by rhinovirus resulted in a more dramatic increase in these transcription factors; however, when rhinovirus-infected cells were treated with Echinacea, transcription factor levels were reduced to low levels 39.
Preparations include juice from the aerial parts of the plant (which contain polysaccharides) and alcoholic tinctures from roots (containing caffeic acid derivatives and alkylamides) stimulated the release of pro-inflammatory factors from uninfected BEAS-2B bronchial epithelial cells. Exposure to Rhinovirus 14 stimulated the release of several chemokines known to attract inflammatory cells, and most these effects were reversed by introduction either of the two Echinacea extracts 91.
These results could explain the anti-inflammatory effects of Echinacea. The rhinovirus type 1A (RV1A) resulted in increased mucopolysaccharide inclusions in the goblet cells of normal human airway epithelial cells; this change was reversed by Echinacea treatment. Echinacea could ameliorate mucus production during colds because mucin secretion stimulated by RV1A is reversed by Echinacea treatment. Echinacea also inhibited secretion of substantial amounts of the pro-inflammatory cytokines IL-6 and IL-8 in RV-infected tissues 92.
The hydroalcoholic extract also pressed juice of E. pallida exhibited anti-viral activity against herpes simplex virus types 1 and 2 (HSV-1, HSV-2) in a dose-dependent manner. Plaque formation was significantly reduced by more than 99% or completely absent. In addition, Echinacea juice revealed anti-viral activity during all phases of the viral replication cycle, protected cells against viral infection by interfering with virus attachment and could interact with herpes virus inside and outside the cell 93.
A polysaccharide isolated from E. purpurea promoted immune response, leading to a reduced latency phase, and it has a promising effect on latency prevention in HSV-1 when supplied before infection 94. The rhinoviruses 1A and 14, influenza virus, respiratory syncytial virus (RSV), adenovirus types 3 and 11, and HSV-1 induced secretion of IL-6 and IL-8, in addition to several other chemokines, depending on the virus; and Echinaforce® inhibited this induction. E. purpurea preparation effectively inhibited the virus-induced cytokine secretion and pro-inflammatory responses induced by all the viruses tested in BEAS-2B human bronchial epithelial cells. This preparation also showed potent virucidal activity against viruses with membranes such as RSV, HSV, and influenza virus, at the oral recommended dose 95.
In an open-label, fixed-sequence study, 50 patients infected by human immunodeficiency virus (HIV) received anti-retroviral therapy including 400 mg etravirine (a non-nucleoside reverse transcriptase inhibitor of HIV) once daily for 4 weeks. Capsules containing E. purpurea root extract were added to the anti-retroviral treatment (500 mg every 8 h) for two weeks.
Results showed that the coadministration of E. purpurea with etravirine was safe and well tolerated in HIV-infected patients 96. Cichoric acid has been shown to inhibit the HIV-type 1 integrase, improved the anti-HIV-1 effect of Zidovudine and protease inhibitor (AG1350) in vitro 97.
Echinaforce® inhibited the growth of three species of trypanosomatids: Leishmania donovani, Leishmania major, and Trypanosoma brucei. L. donovani stimulated the production of the pro-inflammatory IL-6 and IL-8 cytokines in human bronchial epithelial cells and in skin fibroblasts, but Echinaforce® eradicated this stimulation by anti-inflammatory effect 98. By application of purified polysaccharides from cell cultures of E. purpurea, peritoneal macrophages killed cells infected either with the parasite Leishmania enriettii, or with yeast Candida albicans 99.
Extracts from Echinacea inhibited the growth of several yeasts such as Saccharomyces cerevisiae, Candida shehata, C. kefyr, C. albicans, C. steatulytica and C. tropicalis 25. The alkamides from Echinacea acted synergistically to disrupt the fungal cell wall and cell membrane, a target for specific inhibition of fungal pathogens.
- cerevisiae cells exposed to sub-inhibitory concentrations of synthetic alkamides and Echinacea extract exhibit increased frequencies of cell wall damage and death, which were comparable to caspofungin and significantly greater than hygromycin and nourseothricin, which inhibit protein synthesis 100. These results provide evidence that bacterial, viral, and fungal infections could be halted by Echinacea administration.
The Common Cold and Upper Respiratory Infections: The common cold is one of the most common illnesses worldwide, coupled with a lack of specific treatment options which invites to evaluate alternative therapies such as herbal remedies. Nowadays, Echinacea is possibly the most recognized herbal supplement for the prevention and treatment of colds.
Many people believe that Echinacea can boost the immune system and reduce the severity and the frequency of cold symptoms. This plant is widely used to fight the common cold and other upper respiratory infections in the United States and Europe, nevertheless, some studies of Echinacea for the common cold have not found that it really helps. The clinical effectiveness of Echinacea is controversial because clinical trials have had mixed results; some studies have shown clinical benefit, whereas others have not (summarized in Table 2).
Some studies showed that Echinacea could reduce duration, severity, and frequency of symptoms of cold and URIs. Hoheisel et al., in a double-blind study found that E. purpurea pressed juice reduced the duration and the severity of colds. In this study, 120 people were given E. purpurea or a placebo as soon as they started showing signs of getting a cold. Treatment with Echinacea at the early onset of cold or flu symptoms was effective for relieving these symptoms in a shorter period 11.
The results from a clinical study suggested that treatment with Echinaforce® can be recommended as a prophylactic treatment. Long-term treatment with Echinaforce® was associated with a significant reduction in both total number and severity of cold episodes, whereas it did not induce any health risk above that reported with the placebo treatment 101.
In a double-blind trial, 246 healthy adult volunteers with recent onset of respiratory infection were given either Echinaforce®, E. purpurea concentrate (same preparation at 7 times higher concentration), special E. purpurea radix preparation or placebo until they felt healthy again but not longer than 7 days. Echinaforce® and its concentrated preparation were significantly more effective than the special Echinacea extract or placebo.
All treatments were well tolerated, and among the Echinacea groups, the frequency of adverse events was not significantly higher than in the placebo group 102.
In a randomized, double-blind, placebo-controlled trial, 282 subjects with a history of two or more colds in the previous year, but otherwise in good health, were recruited. They were instructed to start Echinilin (a formulation prepared from freshly harvested E. purpurea and standardized by active components alkamides, cichoric acid, and polysaccharides) or placebo at the onset of the first symptom related to cold for seven days.
The total daily symptom scores were found lower in the Echinilin group, and the response rate to treatments was greater in the treated group. Early intervention with a standardized formulation of Echinacea resulted in reduced symptom severity in subjects with naturally acquired upper respiratory tract infection 103.
In a study, Echinilin was administered to 150 adults at the onset of their cold for one week, with eight doses (5 ml/dose) on day 1 and three doses on the subsequent days. Researchers observed it decreased daily symptomatic scores and sustained increase in the number of circulating total white blood cells, monocytes, neutrophils, and NK cells in the Echinacea group versus the placebo group. These results suggest that Echinilin, by enhancing the non-specific immune response and stimulating free radical scavenging properties, may have led to a faster resolution of the cold symptoms 104.
In one double-blind placebo-controlled study, a total of 95 subjects with early symptoms of cold or flu (runny nose, scratchy throat, fever) were randomly assigned to receive an Echinacea herbal tea preparation (Echinacea Plus) 5-6 cups/day titrating to 1 over 5 days or placebo, the study period was 3 months. There was a significant difference between the Echinacea and placebo group, also there were no negative effects reported by any of the subjects in either group 10. 473 patients with early influenza symptoms randomized to either 5 days of oseltamivir followed by 5 days of placebo, or 10 days of an E. purpurea-based formulation called Echinaforce Hot drink (Switzerland).
According to the results, Echinaforce Hot drink is as effective as oseltamivir in the early treatment of influenza infections with a reduced risk of complications and adverse events 105. In a prospective, double-blind, randomized study, 62 patients with symptoms of the common cold were treated with a natural multiherbal formula Immumax (containing Echinacea extract, garlic powder, Nigella sativa oil, and Panax ginseng extract plus vitamin C and zinc) for the duration of their symptoms or a maximum of 2 weeks.
The results indicated that Immumax helped reduce the duration and severity of common cold symptoms, and the symptoms resolved faster in the Immumax group than in the placebo group. The median time to resolution of all symptoms was 8 days in the placebo group and 4 days in the Immumax group 106. An herbal compound of E. angustifolia, Arabinogalactan, Vitamin C, Beta- Glucan e Zinc (Imoviral® Junior) was given to 37 children affected by recurrent pharyngotonsillitis or otitis media. Almost all children after six months reported a reduction in the frequency of acute episodes.
Imoviral® Junior can improve the quality of life in pediatric patients affected by recurrent pharyngotonsillitis and otitis media without adverse effects 107. URIs frequently cause exacerbations of chronic obstructive pulmonary disease (COPD). In a double-blind, randomized placebo-controlled trial in COPD patients with acute URI, the combination of E. purpurea along with micronutrients zinc, selenium and vitamin C may alleviate COPD exacerbations caused by acute URI 108.
In contrast to abovementioned results, some studies have reported no statistically significant improvement with Echinacea for the common cold. Taylor et al., 109 using a large randomized controlled trial found no evidence of E. purpurea help in children suffering from URIs. Results of this trial do not support a benefit of Echinacea in the treatment of common cold symptoms in children, and its use was associated with an increased risk of rash. However, the authors concluded that their findings are not transferable to Echinacea use in adults or other species/preparations of Echinacea. In another randomized, double-blind placebo-controlled design, 128 adults received either 100 mg of E. purpurea (freeze-dried pressed juice from the aerial parts) or placebo 3 times daily until cold symptoms were relieved up to a maximum of two weeks.
The time to resolution of symptoms was not statistically different, and no significant difference was observed between treatment groups for symptoms including sneezing, nasal discharge, nasal congestion, headache, sore or scratchy throat, hoarseness, muscle pain, and cough 110. A total of 109 patients with a history of more than three colds or respiratory infections in the previous year were randomly assigned to receive 4 ml E. purpurea fluid extract twice a day in a double-blind study.
Treatment with E. purpurea did not significantly decrease the incidence, duration or severity of colds and respiratory infections compared to placebo. Adverse events were observed in 20% of patients in the Echinacea group compared with 13% of patients in the placebo group 111.
In a randomized, double-blind clinical trial 58 subjects were assigned to survey the effects of Echinacea on the frequency of upper respiratory symptoms. Individuals in the Echinacea group reported 9 sick days during 8 weeks, whereas the placebo group reported 14 sick days. No difference was found in the frequency of upper respiratory tract symptoms and total symptom days for patients taking prophylactic Echinacea for the 8-week period compared with those taking parsley capsules.
The findings suggest that Echinacea does not have a meaningful effect on respiratory tract infection symptoms.112 In a large randomized study on 713 patients, Barrett et al. found that dried E. purpurea and E. angustifolia root (10.2 g for the first 24 h of a cold and 5.1 g for the next 4 days) did not improve symptoms more than placebo or no treatment. Change in IL-8 levels and neutrophil counts were also not statistically significant in the no-pill group 113.
Barret et al. in another randomized, double-blind placebo-controlled study on adults with colds concluded E. angustifolia and E. purpurea does not have an expressive effect 114. In a double-blind trial by Melchart et al., 302 healthy volunteers were given an alcohol tincture containing either E. purpurea root, E. angustifolia root, or placebo for 12 weeks. The results showed that E. purpurea and E. angustifolia decreased the number of people who got sick; however, the difference was not statistically significant 115. Three meta-analyses evaluated the effect of Echinacea on incidence, duration, and prevention of the common cold and induced rhinovirus infections 12-14. Schoop et al., performed a meta-analysis of experimental rhinovirus infection studies with humans to determine whether the negative results obtained in previous studies were a consequence of efficacy or inadequate sample size. A total of 234 articles were identified through the literature search; and based on the analysis, the likelihood of experiencing a clinical cold was 55% higher with placebo than with Echinacea. This meta-analysis exhibited standardized extracts of Echinacea were effective in the prevention of symptoms of the common cold after clinical inoculation, compared with placebo 12. Shah et al. did meta-analysis reviewed Echinacea clinical trials that examined both prevention and treatment in the incidence and duration of the common cold.
The results supported Echinacea’s benefit in decreasing the incidence and duration of the common cold.13 Evidence from another meta-analysis with a total of 2458 participants by Schapowal et al. indicated that the use of Echinacea potently reduced the risk of recurrent respiratory infections and the development of complications. Ethanolic extracts from Echinacea appeared to be more effective than pressed juices and increased dosing during acute episodes further enhanced these effects 14. A Cochrane review by Karsch-Völk et al. 116 Compared the effect of Echinacea to placebo, in the treatment and the prevention of the common cold. They reviewed twenty-four double-blind controlled clinical trials with 4631 participants investigating the effectiveness of several different Echinacea preparations for preventing and treating common colds or induced rhinovirus infections. The authors concluded that Echinacea products have not proved statistically significant in reducing illness occurrence, although there might be a weak benefit from some Echinacea products.
TABLE 2: CLINICAL TRIALS AND HUMAN STUDIES ON EFFICACY OF ECHINACEA AGAINST COMMON COLD AND UPPER RESPIRATORY TRACT INFECTIONS
|Intervention||Study population||Type of study||Comparator||Dosage/Treatment period||Outcome||References|
|Tea preparation from aerial parts of E. purpurea and E. angustifolia, and E. purpurea root||patients with the earliest symptoms of a cold||RCT||Placebo||5 to 6 cups day 1, titration to one cup on day 5/ 5 days||Positive||10|
|Pressed juice of E. purpurea herb (Echinacin®)||patients with symptoms of a cold||RCT||Placebo||20 drops every 2 h on day 1 followed by 3 × 20 drops/day/ 10 days||Positive||11|
|Echinaforce® (alcoholic extraction from freshly harvested E. purpurea with 95% herb and 5% roots)||healthy adults||RCT||Placebo||for illness prevention: 3 × 0.9 ml/day; in case of cold: 5 × 0.9ml/day/ 4 months||Positive||101|
|Echinaforce® tablets (E. purpurea crude extract based on 95% herb/5% roots)||healthy volunteers||RCT||Placebo||2 × 3 (40.68 mg/day)/ maximum one week||Positive||102|
|Freshly harvested E. purpurea and standardized by active components alkamides, cichoric acid and polysaccharides (Echinilin®)||healthy adults||RCT||Placebo||10 × 4 ml the first day, then 4 × 4 ml/ 7 days||Positive||103|
|E. purpurea (Echinilin®)||adults at the onset of their cold||RCT||Placebo||8 × 5 ml for day 1, then 3 × 5 ml for 6 days/ one week||Positive||104|
|Syrup of E. purpurea herb harvested at flowering||healthy children||RCT||Placebo||3.75 ml twice a day for ages 2-5 years and 5 ml twice a day for ages 6-11 years/ 10 days||Negative||109|
|Echinacea fresh capsule (freeze-dried pressed juice from E. purpurea)||patients with cold||RCT||Placebo||3 × 1 capsule/day/ maximum 14 days||Negative||110|
|Pressed juice of E. purpurea (Echinacin®)||patients with symptoms of a cold||RCT||Placebo||2 × 4 ml daily/ 8 weeks||Negative||111|
|Capsules of E. purpurea dried plant||healthy adults||RCT||Placebo||3 × 2 capsules/day (1 capsule containing 300 mg E. purpurea)/ 8 weeks||Negative||112|
|Tablets containing E. purpurea root and E. angustifolia root||individuals with cold symptoms||RCT||Placebo||4 × 2 tablets during the first day, then 4 × 1 tablet per day for the next 4 days/ 5 days||Negative||113|
|Capsules containing 50% E. angustifolia root, 25% E. purpurea root, 25% E. purpurea herb||patients with active cold||RCT||Placebo||6 × 4 capsules on the first day, then 3 × 4 capsules up to 10 days/ 10 days||Negative||114|
|E. Purpurea/ E. angustifolia root alcoholic extract||healthy volunteers||RCT||Placebo||50 drops twice a day/ 12 weeks||Negative||115|
RCT = Double-blind, randomized, controlled trial
Studies of Echinacea for the common cold have had mixed results, and whether or not Echinacea helps prevent or treat the common cold remains under debate. There are many variables in studying Echinacea for the common cold and URIs.
All studies to date have had essential limitations, including differences in trial design, use of different species and plant parts (containing different constituents), various routes of administration, sample size, monitoring responses of healthy subjects, analytical methodology, and choice of biomarker and placebo. These differences make it hard to compare the results; consequently, these data do not allow clear conclusions whether Echinacea might be effective for this purpose or not.
Hepatoprotective Effects: Chicoric acid may reduce acute alcohol-induced steatosis in mice through interfering with the induction of iNOS and iNOS-dependent signaling pathways in the liver. Acute alcohol administration caused a significant increase in hepatic triacylglycerols accumulation, which was associated with increase in 4-hydroxynonenal protein adducts, and iNOS and active plasminogen activator inhibitor 1 protein level in the liver; pretreatment with chicoric acid for 4 days before ethanol ingestion significantly attenuated these alcohol effects on the liver.
In RAW264.7 macrophages, treatment with chicoric acid (4 mg/kg body weight) suppressed LPS-induced TNF-α and iNOS at mRNA expression level 23. E. purpurea extract had a protective role on kidney and liver against diethylnitrosamine (DEN) toxicity in rats. One month administration of DEN caused an elevation in serum alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP), creatinin and total and direct bilirubin levels in serum; however these factors decreased in E. purpurea administration. Also, the histopatho-logical investigation revealed a proliferation of hepatic stellate cells 117. It was found that alkamide dodeca-2E, 4E, 8Z, 10Z(E)-tetraenoic acid isobutylamides isolated from E. purpurea root has hepatoprotective effect against acute fulminant hepatitis induced by lipopolysaccharide/D-galactosamine (LPS/D-GalN) in mice.
This dose-dependently induced HO-1 protein expression in LPS-stimulated murine macrophages that were regulated through an increase in JNK phosphorylation, c-jun protein expression, and phosphorylation, and transcription factor AP-1 binding consensus DNA activity. Besides, this alkamide suppressed serum aminotransferase activities, TNF-α expression, and damages to hepatocytes of LPS/d-GalN-treated mice 118. Cadmium (Cd 2+) is toxic to a wide range of tissues. Prolonged intraperitoneal injection of E. purpurea extract combined with Cd(2+)Cl(2) decreased the mitotic activity induced by Cd 2+, also increased apoptotic activity of hepatocytes of mice 119. These data suggest a new application of Echinacea as a hepatoprotective agent; however further investigation is needed.
Echinacea against Diabetes: Diabetes is a debilitating and often life-threatening problem with increasing incidence throughout the world. A scientific investigation of herbal remedies for diabetes may provide valuable alternative drugs and therapeutic strategies. Recent studies have indicated that Echinacea could have anti-diabetic activities.
Adipogenesis has been used to study the insulin signaling pathway and to screen anti-diabetic compounds. When adipocyte differentiation was induced with insulin plus 3-isobutyl-1-methylxanthine and dexamethasone, the accumulation of lipid droplets and the cellular triglyceride content were increased by ethanolic extract of E. purpurea. The expression of PPAR-γ and CCAAT-enhancer-binding protein (C-EBP)α in 3T3-L1 adipocytes-treated with dodeca-2(E),4(E)-dienoic acid isobutylamide were increased, as well as triglyceride content of adipocytes and fat accumulation, were improved 28. The isomeric C12-alkamides isolated from a dichloromethane root extract of E. purpurea were found to activate PPAR-γ, to increase basal and insulin-dependent glucose uptake in 3T3-L1 adipocytes in a dose-dependent manner, and to exhibit characteristics of a PPAR-γ partial agonist 29.
The alkamide hexadeca-2E,9Z,12Z,14E-tetraenoic acid isobutylamide isolated from an n-hexane extract of E. purpurea flowers was shown to increase insulin-stimulated glucose uptake and to activate PPAR-γ without stimulating adipocyte differentiation 30.
In non-obese diabetic (NOD) mice, supplementation with Echinacea resulted in a significant increase in the absolute numbers of NK cells in the spleen, irrespective of feeding duration; moreover, it stimulated NK cell production in their bone marrow origin site. What’s more, consumption of herb by NOD mice has led to no negative consequences concerning the hemopoietic and immune lineages 120. These data suggest that Echinacea contain compounds with the potential to manage insulin resistance and diabetes.
Effects on Skin Problems: Several plants with effective properties may offer better alternative treatments for skin complications. Echinacea contains many valuable constituents for protection of skin from oxidative stress and for improving skin health. In a survey, E. purpurea extract was incorporated into cream and gel bases, and the effect of those formulations on skin irritation, hydration level, and wrinkle reduction was evaluated in 10 healthy volunteers.
According to results E. purpurea cream and gel were effective in improving skin hydration and reducing wrinkle. Also both formulations showed no irritation to skin 121. Acne is a chronic inflammatory disorder of skin follicles caused by the gram-positive bacterium Propionibacterium acnes. Echinaforce® might provide a useful, safe treatment in the control of acne disease by preventing the proliferation of the organism and inhibiting the bacterial-induced inflammation. In human skin fibroblasts in-vitro, P. acne induced the secretion of considerable amounts of pro-inflammatory cytokines IL-6 and IL-8; however, Echinaforce® completely reversed their level to normal 22. Echinacea is purported to be beneficial for wound healing. It revealed that root extract of E. pallida and its constituent echinacoside has good wound healing properties in excision wounds treated topically. This activity probably related to the anti-hyaluronidase and anti-inflammatory activities of echinacoside 122.
Alcoholic extract of E. pallida accelerated cutaneous wound closure in the stressed mice but had no curing effect for the non-stressed mice. The wound healing effect of Echinacea in stressed mice is not mediated through modulation of glucocorticoid signaling because plasma glucocorticoid in restraint-stressed mice treated with Echinacea didn’t change 123.
Effects on Nervous System: Excitatory synaptic transmission in the hippocampus, a brain region that is involved in anxiety and anxiety-related behaviors, was suppressed by an Echinacea extract; but no change in inhibitory synaptic transmission could be detected upon application of this extract.
Also, at low concentration the Echinacea extract reduced the spiking activity of CA1 pyramidal cells, while at high concentration increased it, this was parallel to the reduction in the magnitude of the h-current-mediated voltage responses in pyramidal cells 124.
Anxiolytic potency of Echinacea preparations was consistently seen in three different laboratory tests of anxiety, the elevated plus-maze, social interaction, and shock-induced social avoidance tests; these effects are comparable with chlordiazepoxide. Echinacea preparations had considerable anxiolytic potential, and it decreased anxiety-like behavior in all tests 125. E. angustifolia extract decreased anxiety in the elevated plus-maze and ameliorated contextual conditioned fear. No lethality or behavioral signs of discomfort were noticed in rats treated with intragastric administration of 1000 and 3000 mg/kg E. angustifolia.
A pharmacological formulation based on the same E. angustifolia extract was tested in healthy volunteers. One or two tablets (each containing 20 mg of the plant extract) per day were administered for 7 days to subjects scoring high on the State-Trait Anxiety Inventory (STAI). The high dose (2 tablets/day) decreased STAI scores within 3 days in human subjects, an effect that remained stable for the duration of the one-week treatment and for the 2 weeks that followed treatment 126. The endocannabinoid system involves many pathophysiological activities including analgesic action.
Echinacea-isolated alkamides appear to exert psychoactive activities through the endocannabinoid system 77.
Alkamides from E. angustifolia roots showed psychoactive properties by binding to CB1 receptors predominantly expressed in the brain tissue 127. The finding of the interaction of alkamides with CB receptors may help explain the traditional use of Echinacea for wound healing, pain relief and improvement of cold symptoms 128.
Effects on the Reproductive System: Two studies raised questions about possible antifertility effects of Echinacea. The histological changes were found after 4 or 8 weeks of using 50 mg/kg E. purpurea in Wistar male rats.
Results of the study showed a significant reduction in the testicle mass and the body mass, as well as changes in histological structures after eight weeks of E. purpurea administration. Consumption of the preparation for 8 weeks caused anti-androgenic variations in cells of the spermatogenic epithelium of a testicle duct and consequently inhibited spermatogenesis 129. An in vitro investigation by fresh sperm specimens exhibited E. purpura at high-concentration interfered with sperm enzymes, possibly the Echinacea treatment may prevent sperm from fertilizing the oocytes. The beat cross frequencies were higher for Echinacea treatment group 130.
Echinacea extract can be a useful medication for the treatment of benign prostate hyperplasia (BPH). Results of work showed a significant decrease of prostate weight of BPH in rats and reversed changes in the structure of the prostate gland after using E. purpurea extract for 8 weeks 84. E. angustifolia extract enhanced cell viability and proliferation in mammary epithelial cells, HC11 mouse cell line and BME-UV bovine cell line.
This effect may be modulated by MAPK and Akt activation and by a reduction of caspase-3 activity in Echinacea treatment. Moreover, Echinacea was able to increase β-casein expression in association with prolactin (5 mg/ml). These data demonstrate that E. angustifolia extract can stimulate mammary epithelial cell physiology and may be considered a candidate to support mammary gland activity during mammogenesis and lactogenesis states 131.
Metabolism and Pharmacokinetics: It is found that the application of herbal medicinal products and their components at the same time with substances that are cytochrome P450 (CYP) enzymes substrates may cause herb-drug interactions. Since the use of herbal supplements continues to increase throughout the world, the potential for drug-herbal interactions also rises.
Modified expression of CYP enzymes will affect drug metabolism in three different ways. It can alter drug elimination, pro-drug activation, or drug bioactivation (such as conversion to toxic metabolites), all of which can have serious consequences 132. Echinacea is a widely used herbal medicinal product, and consequently, studies of its interactions with conventional drugs are of particular importance. It was demonstrated E. purpurea ethanolic extract could potently inhibit the expression of CYP3A1 and CYP3A2, also CYP2D2 and CYP2C6 activities 133. CYP3A4 and CYP2C9 enzymes have been reported to metabolize one of the main alkamide constituents of E. purpurea extract in human liver microsomes 134.
Administration E. purpurea root extract for 8 days to healthy volunteers significantly decreased CYP1A2 activity, increased hepatic CYP3A4 activity, and there was little decrease in CYP2C9 activity. E. purpurea root reduced the oral clearance of substrates of CYP1A2 but not the oral clearance of substrates of CYP2C9 and CYP2D6 135. E. purpurea cause herb-drug interaction by up-regulating CYP1A2, CYP3A4, and MDR1 expression via pregnane X receptor (PXR) activation in human liver carcinoma HepG2 cells 136.
Alkylamide undeca-2 E,4 E/ Z-diene-8,10-diynoic acid isobutylamide correlated well with inhibition of CYP3A4 by Echinaforce® 137. In a clinical study, no significant effect of E. purpurea on midazolam pharmacokinetics was reported in healthy volunteers. E purpurea selectively altered the catalytic activity of CYP3A in the liver vs. intestine, conversely, E. purpurea whole plant extract administration did not significantly alter CYP3A metabolic serum ratios of 1-hydroxymidazolam: midazolam in healthy volunteers 138.
E. purpurea significantly induced cytochrome CYP3A activity but did not alter lopinavir-ritonavir exposure in healthy subjects. Neither lopinavir nor ritonavir (400/100 mg) pharmacokinetics was significantly altered by 2 weeks of E. purpurea coadministration in healthy volunteers. E. purpurea induced CYP3A activity but did not alter lopinavir concentrations, most likely due to the presence of ritonavir as a potent CYP3A inhibitor.
E. purpurea is unlikely to alter the pharmacokinetics of ritonavir-boosted protease inhibitors but may cause a decrease in plasma concentrations of other CYP3A substrates 139. In an open-label, fixed-sequence study the interaction of E. purpurea with etravirine, a non-nucleoside reverse transcriptase inhibitor of HIV was investigated. Fifteen HIV-infected patients receiving etravirine (400 mg once daily) for 4 weeks, and E. purpurea root extract (500 mg every 8 h) was added to the anti-retroviral treatment for 14 days. Results showed that the coadministration of E. purpurea with etravirine was safe and well tolerated in HIV-infected patients 96.
The multidrug transporter P-glycoprotein (P-gp), the product of the ABCB1 gene, involved in cancer multidrug resistance (MDR) and in herb-drug or drug-drug interactions. Concomitant administration of medicinal herbs with drugs that are P-gp substrates may produce clinically significant herb-drug interactions. P-glycoprotein is responsible for exporting xenotoxins including pharmaceutical medicines from the cell.
Alkamides isolated from E. angustifolia inhibited P-gp-mediated calcein transport a major constituent of the blood-brain barrier in isolated porcine brain capillary endothelial cells 140. The n-hexane root extracts from E. pallida, E. angustifolia, and E. purpurea reduced the efflux of the P-gp probe calcein-AM from human proximal tubule HK-2 cells (that constitutively expresses ABCB1). Pentadeca-(8 Z,13 Z)-dien-11-yn-2-one isolated from the n-hexane extract of E. pallida roots was an efficient compound that reduced P-gp activity and decreased the calcein-AM efflux 141. The interaction of E. purpurea with P-gp transporter was studied in human adenocarcinoma colonic cell line Caco-2, as a standard rapid, reliable, and low-cost model for study the absorption of drugs by the intestine.
In a study, digoxin was used as a substrate and verapamil as a control inhibitor. At high concentrations of E. purpurea, a significant linear decrease was observed in the net digoxin flux, indicating a dose-dependent inhibitory effect of E. purpurea on P-gp 142.
Commonly used herbal supplements were screened for their potential to inhibit UDP-glucuronysl transferase 1A1 (UGT1A1) activity using human liver microsomes. Echinacea showed inhibition of UGT1A1 activity 143. Alkamides and cinnamic acid have been shown to have good permeability through human Caco-2 cells, although caftaric acid, echinacoside, and cichoric acid permeated poorly through the Caco-2 monolayers 144.
These findings suggest that Echinacea and components may influence the metabolism of different drugs also alter their pharmacokinetics. However, further studies are also needed to confirm the potential of interactions between Echinacea and other conventional drugs.
Safety and Toxicity: The increasing use of medicinal herbs among the populations has created the need for scientific research to determine the safety of herbs. Herbal remedies and dietary supplements are not classified as drugs by the US Food and Drug Administration (FDA); therefore, although the 1994 Dietary Supplement Health and Education Act allows manufacturers to make claims intended to influence public opinion regarding the benefits of these products, herbs and supplements are excepted from the rigorous regulations required for drugs.
Echinacea has an excellent safety record and is well tolerated by most consumers. Oral administration of the E. purpurea expressed juice for 4 weeks proved virtually non-toxic to rats and mice, even in doses many times greater than human therapeutic dose 145.
There are reports of anti-apoptotic activity of E. angustifolia extract on noncancerous cells. The biological effect of E. angustifolia extract on cell viability, and cell differentiation in mammary epithelial cells have been observed in two different cell lines HC11 and BME-UV. This herb activated MAPK/Akt pathway involved in cell viability and proliferation and prevention of caspase-3 accumulation that indicates an anti-apoptotic effect of Echinacea extract 131. Moreover, hydroalcoholic extract and pressed juice from E. pallida exhibited a low cytotoxic effect on monkey kidney cell cultures 146.
Cleft palate is one of the most common birth defects. E. purpurea extract had a prophylactic effect on the incidence of phenytoin-induced cleft palate. In a study, the prophylactic effects of levamisole and Echinacea extract on teratogenic effects of phenytoin were compared.
This study was performed on pregnant mice that received phenytoin at 10th day of gestation, E. purpurea extract was administrated at a dose of 360 mg/kg intraperitoneally, along with and 12 hours after phenytoin injection. Cleft palate incidence decreased in fetuses of mice that received phenytoin with Echinacea extract; also mean weight and length of fetuses of the ones that received Echinacea were significantly greater than those received only phenytoin 147.
The teratogenic effect of phenytoin on the cleft palate is associated with inhibition of cell proliferation and increase in cell apoptosis of mouse embryonic palatal mesenchymal (MEPM) cells, and E. purpurea extract had the reverse effect 148.
On the other side of safety, there are rare cases of adverse effects. Such side effects include nausea, abdominal pain, diarrhea, itch, and rash. Echinacea has also been linked to allergic reactions, including asthma, shortness of breath, and one case of anaphylaxis 149. Echinacea can be associated with allergic reactions that may be severe or exacerbate asthma 149. Moreover, it has also been incriminated in causing contact dermatitis and anaphylactic reactions associated with the consumption of Echinacea 150.
In clinical trials, gastrointestinal symptoms were common. Echinacea supplementation has altered the gastrointestinal tract microbiota. In study 50 human subjects consumed 1000 mg of standardized E. purpurea for 10 days. Significant increases were found for total aerobic bacteria, Bacteroides group, and Bacteroides fragilis after E. purpurea exposure 151. There are concerns that by stimulating immune function, Echinacea could potentially exacerbate autoimmune diseases and decrease the effectiveness of immunosuppressive drugs, but this warning is based on theoretical considerations rather than human analyses.
Its immunostimulatory property may lead to interference with immunosuppressant agents; therefore a consensus exists about the avoidance of Echinacea in patients who are being administered immunosuppressive drugs, especially in patients undergoing organ transplantation. However, despite the immunostimulatory effect that may be seen with short-term use, chronic long-term use (>6-8 weeks) of Echinacea may be immunosuppressive 152 which increases the risks of poor wound healing and opportunistic infections.
Consequently, its use in AIDS or autoimmune disorders such as multiple sclerosis and rheumatoid arthritis is controversial. Furthermore, there are also concerns about its potential hepato-toxicity, probably the use of Echinacea in combination with other drugs metabolized by the liver can cause possible unwanted effects; thus this plant should be used carefully in patients with pre-existing hepatic dysfunctions. So altogether, while Echinacea administration appears to be without significant adverse effects, the full toxicological profile of Echinacea remains to be assessed.
CONCLUSION: Echinacea is one of the most important medicinal herbs. In a 2007 National Center for Complementary and Alternative Medicine survey, Echinacea was the third most commonly used non-vitamin, non-mineral natural product among adults, and the fifth highest selling herbal dietary supplement 153. At present, extracts and plant products made from Echinacea purpurea, E. angustifolia, and E. pallida comprise one of the largest parts of the herbal medicine market, in North America as well as in Europe.
Echinacea is widely used as one of the treatments chosen by consumers with the belief that it will reduce the severity and duration of the common cold and because of its supposed beneficial effects on the immune system. There are multiple scientific studies published to evaluate the effects of Echinacea on common cold and immunity; however, results are controversial and inconclusive.
It is well known that the effectiveness of distinct Echinacea products differs considerably, mainly due to the use of different parts of the plant (including leaves, flowers, root or rhizome), extraction protocols, and the addition of other components. These all have made their outcomes difficult to interpret and compare.
Different commercial products are likely to contain different relative concentrations of active constituents, and there are currently no regulated manufacturing standards for the amount of individual chemical compounds in commercial preparations. Also, the dose and timing of administration also need to be evaluated extensively.
Results show that among the bioactive compounds present in Echinacea, alkylamides, cichoric acid and polysaccharides have most effects. However, the biological impacts of unidentified compounds in this herb should be also investigated.
Despite many pharmacological and clinical studies, the molecular mechanisms for Echinacea which exert its effects are not well understood. Additionally, more scientific research is required regarding its safety and adverse effects.
CONFLICT OF INTEREST: None declared.
- Brenes A and Roura E: Essential oils in poultry nutrition: main effects and modes of action. Anim Feed Sci Technol 2010; 158: 1-14.
- Barnes J, Anderson LA, Gibbons S and Phillipson JD: Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2005; 57: 929-54.
- Percival SS: Use of echinacea in medicine. Biochem Pharmacol 2000; 60: 155-8.
- Newall CA, Anderson LA, Phillipson JD: Herbal medicine: a guide for health care professionals, London: The Pharmaceutical Press 1996.
- Wang CY, Chiao MT, Yen PJ, Huang WC, Hou CC and Chien SC: Modulatory effects of Echinacea purpurea extracts on human dendritic cells: a cell- and gene-based study. Genomics 2006; 88: 801-8.
- Rehman J, Dillow JM, Carter SM, Chou J, Le B and Maisel AS: Increased production of antigen-specific immunoglobulins G and M following in-vivo treatment with the medicinal plants Echinacea angustifolia and Hydrastis canadensis. Immunol Lett 1999; 68: 391-5.
- Benson JM, Pokorny AJ, Rhule A, Wenner CA, Kandhi V and Cech NB: Echinacea purpurea extracts modulate murine dendritic cell fate and function. Food Chem Toxicol 2010; 48: 1170-7.
- Roesler J, Emmendörffer A, Steinmüller C, Luettig B, Wagner H and Lohmann-Matthes ML: Application of purified polysaccharides from cell cultures of the plant Echinacea purpurea to test subjects mediates activation of the phagocyte system. Int J Immunopharmacol 1991; 13: 931-41.
- Sasagawa M, Cech NB, Gray DE, Elmer GW and Wenner CA: Echinacea alkylamides inhibit interleukin-2 production by Jurkat T cells. Int Immunopharmacol 2006; 6: 1214-21.
- Lindenmuth GF and Lindenmuth EB: The efficacy of echinacea compound herbal tea preparation on the severity and duration of upper respiratory and flu symptoms: a randomized, double-blind placebo-controlled study. J Altern Complement Med 2000; 6: 327-34.
- Hoheisel O, Sandberg M, Bertram S, Bulitta M and Schaffer M: Echinagard treatment shortens the course of the common cold: a doubleblind, placebo-controlled clinical trial. Euro J Clin Res 1997; 9: 261-268.
- Schoop R, Klein P, Suter A and Johnston SL: Echinacea in the prevention of induced rhinovirus colds: a meta-analysis. Clin Ther 2006; 28:174-83.
- Shah SA, Sander S, White CM, Rinaldi M and Coleman CI: Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. Lancet Infect Dis 2007; 7: 473-80.
- Schapowal A, Klein P and Johnston SL: Echinacea reduces the risk of recurrent respiratory tract infections and complications: a meta-analysis of randomized controlled trials. Adv Ther 2015; 32: 187-200.
- Zhai Z, Solco A, Wu L, Wurtele ES, Kohut ML and Murphy PA: Echinacea increases arginase activity and has anti-inflammatory properties in RAW 264.7 macrophage cells, indicative of alternative macrophage activation. J Ethnopharmacol 2009; 122: 76-85.
- Hou CC, Chen CH, Yang NS, Chen YP, Lo CP and Wang SY: Comparative metabolomics approach coupled with cell- and gene-based assays for species classification and anti-inflammatory bioactivity validation of Echinacea plants. J Nutr Biochem 2010; 21: 1045-59.
- Hu C and Kitts DD: Studies on the antioxidant activity of Echinacea root extract. J Agric Food Chem 2000; 48: 1466-72.
- Abouelella AM, Shahein YE, Tawfik SS and Zahran AM: Phytotherapeutic effects of Echinacea purpurea in gamma-irradiated mice. J Vet Sci 2007; 8: 341-51.
- Tsai YL, Chiu CC, Yi-Fu Chen J, Chan KC and Lin SD: Cytotoxic effects of Echinacea purpurea flower extracts and cichoric acid on human colon cancer cells through induction of apoptosis. J Ethnopharmacol 2012; 143: 914-9.
- Chicca A, Adinolfi B, Pellati F, Orlandini G, Benvenuti S and Nieri P: Cytotoxic activity and G1 cell cycle arrest of a Dienynone from Echinacea pallida. Planta Med 2010; 76: 444-6.
- Currier NL and Miller SC: The effect of immunization with killed tumor cells, with/without feeding of Echinacea purpurea in an erythroleukemic mouse model. J Altern Complement Med 2002; 8: 49-58.
- Sharma M, Schoop R, Suter A and Hudson JB: The potential use of Echinacea in acne: control of Propionibacterium acnes growth and inflammation. Phytother Res 2011; 25: 517-21.
- Landmann M, Kanuri G, Spruss A, Stahl C and Bergheim I: Oral intake of chicoric acid reduces acute alcohol-induced hepatic steatosis in mice. Nutrition 2014; 30: 882-9.
- Sharma SM, Anderson M, Schoop SR and Hudson JB: Bactericidal and anti-inflammatory properties of a standardized Echinacea extract (Echinaforce): dual actions against respiratory bacteria. Phytomedicine 2010; 17: 563-8.
- Binns SE, Purgina B, Bergeron C, Smith ML, Ball L and Baum BR: Light-mediated antifungal activity of Echinacea extracts. Planta Med 2000; 66: 241-4.
- Pleschka S, Stein M, Schoop R and Hudson JB: Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV). Virol J 2009; 6: 197.
- Moltó J, Valle M, Miranda C, Cedeño S, Negredo E and Barbanoj MJ: Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients. Antimicrob Agents Chemother 2011; 55:326-30.
- Shin DM, Choi KM, Lee YS, Kim W, Shin KO and Oh S: Echinacea purpurea root extract enhances the adipocyte differentiation of 3T3-L1 cells. Arch Pharm Res 2014; 37: 803-12.
- Kotowska D, El-Houri RB, Borkowski K, Petersen RK, Fretté XC and Wolber G: Isomeric C12-alkamides from the roots of Echinacea purpurea improve basal and insulin-dependent glucose uptake in 3T3-L1 adipocytes. Planta Med 2014; 80: 1712-20.
- Christensen KB, Petersen RK, Petersen S, Kristiansen K and Christensen LP: Activation of PPARgamma by metabolites from the flowers of purple coneflower (Echinacea purpurea). J Nat Prod 2009; 72: 933-7.
- McGregor RL: The taxonomy of the genus Echinacea (Compositae). Univ. Kansas Sci. Bull 1968; 48: 113-42.
- Binns SED, Baum BR and Arnason JT: A taxonomic revision of Echinacea (Asteraceae: Heliantheae). Syst Bot 2002; 27: 610-32.
- Gilroy CM, Steiner JF, Byers T, Shapiro H and Georgian W: Echinacea and truth in labeling. Arch Intern Med 2003; 163: 699-704.
- Pellati F, Calò S and Benvenuti S: High-performance liquid chromatography analysis of polyacetylenes and polyenes in pallida by using a monolithic reversed-phase silica column. J Chromatogr A 2007; 1149: 56-65.
- Cheminant A, Zawatzky R, Becker H and Brouillard R: Caffeoyl conjugates from Echinacea species: structures and biological activity. Phytochemistry 1988; 27: 2787-94.
- Dong GC, Chuang PH, Forrest MD, Lin YC and Chen HM: Immuno-suppressive effect of blocking the CD28 signaling pathway in T-cells by an active component of Echinacea found by a novel pharmaceutical screening method. J Med Chem 2006; 49: 1845-54.
- Perry NB, Burgess EJ and Glennie VL: Echinacea standardization: analytical methods for phenolic compounds and typical levels in medicinal species. J Agric Food Chem 2001; 49: 1702-6.
- Binns SE, Livesey JF, Arnason JT and Baum BR: Phytochemical variation in echinacea from roots and flowerheads of wild and cultivated populations. J Agric Food Chem 2002; 50: 3673-87.
- Sharma M, Arnason JT and Hudson JB: Echinacea extracts modulate the production of multiple transcription factors in uninfected cells and rhinovirus-infected cells. Phytother Res 2006; 20: 1074-9.
- Altamirano-Dimas M, Sharma M and Hudson JB: Echinacea and anti-inflammatory cytokine responses: Results of a gene and protein array analysis. Pharm Biol 2009; 47: 500-508.
- Lalone CA, Huang N, Rizshsky L, Yum MY, Singh N and Hauck C: Enrichment of Echinacea angustifolia with Bauer alkylamide 11 and Bauer ketone 23 increased anti-inflammatory potential through interference with cox-2 enzyme activity. J Agric Food Chem 2010; 58: 8573-84.
- Pomari E, Stefanon B and Colitti M: Effect of plant extracts on H2O2-induced inflammatory gene expression in macrophages. J Inflamm Res 2014; 7: 103-12.
- Senchina DS, McCann DA, Flinn GN, Wu L, Zhai Z and Cunnick JE: Echinacea tennesseensis ethanol tinctures harbor cytokine- and proliferation-enhancing capacities. Cytokine 2009; 46: 267-72.
- Zhai Z, Liu Y, Wu L, Senchina DS, Wurtele ES and Murphy PA: Enhancement of innate and adaptive immune functions by multiple Echinacea species. J Med Food 2007; 10: 423-34.
- LaLone CA, Rizshsky L, Hammer KD, Wu L, Solco AK and Yum M: Endogenous levels of Echinacea alkylamides and ketones are important contributors to the inhibition of prostaglandin E2 and nitric oxide production in cultured macrophages. J Agric Food Chem 2009; 57: 8820-30.
- Hinz B, Woelkart K and Bauer R: Alkamides from Echinacea inhibit cyclooxygenase-2 activity in human neuroglioma cells. Biochem Biophys Res Commun 2007; 360: 441-6.
- Zhang X, Rizshsky L, Hauck C, Qu L, Widrlechner MP and Nikolau BJ: Bauer ketones 23 and 24 from Echinacea paradoxa paradoxa inhibit lipopolysaccharide-induced nitric oxide, prostaglandin E2 and cytokines in RAW264.7 mouse macrophages. Phytochemistry 2012; 74: 146-58.
- Fast DJ, Balles JA, Scholten JD, Mulder T and Rana J: Echinacea purpurea root extract inhibits TNF release in response to Pam3Csk4 in a phosphatidylinositol-3-kinase dependent manner. Cell Immunol 2015; 297: 94-9.
- Jiang L, Li W, Wang Y, Zhang X, Yu D and Yin Y: Effects of cichoric acid extract from Echinacea purpurea on collagen-induced arthritis in rats. Am J Chin Med 2014; 42: 679-92.
- Tubaro A, Tragni E, Del Negro P, Galli CL and Della Loggia R: Anti-inflammatory activity of a polysaccharidic fraction of Echinacea angustifolia. J Pharm Pharmacol 1987; 39: 567-9.
- Thygesen L, Thulin J, Mortensen A, Skibsted LH and Molgaard P: Antioxidant activity of cichoric acid and alkamides from Echinacea purpurea, alone and in combination. Food Chem 2007; 101: 74-81.
- Dalby-Brown L, Barsett H, Landbo AK, Meyer AS and Mølgaard P: Synergistic antioxidative effects of alkamides, caffeic acid derivatives, and polysaccharide fractions from Echinacea purpurea on in-vitro oxidation of human low-density lipoproteins. J Agric Food Chem 2005; 53: 9413-23.
- Joksić G, Petrović S, Joksić I and Leskovac A: Biological effects of Echinacea purpurea on human blood cells. Arh Hig Rada Toksikol 2009; 60: 165-72.
- Mishima S, Saito K, Maruyama H, Inoue M, Yamashita T and Ishida T: Antioxidant and immuno-enhancing effects of Echinacea purpurea. Biol Pharm Bull 2004; 27:1004-9.
- Goel V, Chang C, Slama J, Barton R, Bauer R and Gahler R: Echinacea stimulates macrophage function in the lung and spleen of normal rats. J Nutr Biochem 2002; 13: 487.
- Cundell DR, Matrone MA, Ratajczak P and Pierce JD: The effect of aerial parts of Echinacea on the circulating white cell levels and selected immune functions of the aging male Sprague-Dawley rat. Int Immunopharmacol 2003; 3: 1041-8.
- Burger RA, Torres AR, Warren RP, Caldwell VD and Hughes BG: Echinacea-induced cytokine production by human macrophages. Int J Immunopharmacol 1997; 19: 371-9.
- Sullivan AM, Laba JG, Moore JA and Lee TD: Echinacea-induced macrophage activation. Immunopharmacol Immunotoxicol 2008; 30: 553-74.
- Rininger JA, Kickner S, Chigurupati P, McLean A and Franck Z: An immunopharmacological activity of Echinacea preparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells. J Leukoc Biol 2000; 68: 503-10.
- Randolph RK, Gellenbeck K, Stonebrook K, Brovelli E, Qian Y and Bankaitis-Davis D: Regulation of human immune gene expression as influenced by a commercial blended Echinacea product: preliminary studies. Exp Biol Med (Maywood) 2003; 228: 1051-6.
- Ritchie MR, Gertsch J, Klein P and Schoop R: Effects of Echinaforce® treatment on ex-vivo-stimulated blood cells. Phytomedicine 2011; 18: 826-31.
- Dapas B, Dall'Acqua S, Bulla R, Agostinis C, Perissutti B and Invernizzi S: Immunomodulation mediated by a herbal syrup containing a standardized Echinacea root extract: a pilot study in healthy human subjects on cytokine gene expression. Phytomedicine 2014; 21: 1406-10.
- Currier NL and Miller SC: Natural killer cells from aging mice treated with extracts from Echinacea purpurea are quantitatively and functionally rejuvenated. Exp Gerontol 2000; 35: 627-39.
- Currier NL and Miller SC: Echinacea purpurea and melatonin augment natural-killer cells in leukemic mice and prolong life span. J Altern Complement Med 2001; 7: 241-51.
- Gan XH, Zhang L, Heber D and Bonavida B: Mechanism of activation of human peripheral blood NK cells at the single cell level by Echinacea water soluble extracts: recruitment of lymphocyte-target conjugates and killer cells and activation of programming for lysis. Int Immunopharmacol 2003; 3: 811-24.
- Fonseca FN, Papanicolaou G, Lin H, Lau CB, Kennelly EJ and Cassileth BR: Echinacea purpurea (L.) Moench modulates human T-cell cytokine response. Int Immunopharmacol 2014; 19: 94-102.
- Matthias A, Banbury L, Bone KM, Leach DN and Lehmann RP: Echinacea alkylamides modulate induced immune responses in T-cells. Fitoterapia 2008; 79: 53-8.
- Wagner H and Jurcic K: Immunological studies of Revitonil, a phytopharmaceutical containing Echinacea purpurea and Glycyrrhiza glabra root extract. Phytomedicine 2002; 9: 390-7.
- Kim HR, Oh SK, Lim W, Lee HK, Moon BI and Seoh JY: Immune-enhancing effects of Echinacea purpurea root extract by reducing regulatory T cell number and function. Nat Prod Commun 2014; 9: 511-4.
- Yamada K, Hung P, Park TK, Park PJ and Lim BO: A comparison of the immunostimulatory effects of the medicinal herbs Echinacea, Ashwagandha and Brahmi. J Ethnopharmacol 2011; 137: 231-5.
- Classen B, Thude S, Blaschek W, Wack M and Bodinet C: Immunomodulatory effects of arabinogalactan-proteins from Baptisia and Echinacea. Phytomedicine 2006; 13: 688-94.
- See DM, Broumand N, Sahl L and Tilles JG: In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. Immunopharmacol 1997; 35: 229-35.
- Steinmüller C, Roesler J, Gröttrup E, Franke G, Wagner H and Lohmann-Matthes ML: Polysaccharides isolated from plant cell cultures of Echinacea purpurea enhance the resistance of immunosuppressed mice against systemic infections with Candida albicans and Listeria mono-cytogenes. Int J Immunopharmacol 1993; 15: 605-14.
- Morazzoni P, Cristoni A, Di Pierro F, Avanzini C, Ravarino D and Stornello S: In-vitro and in-vivo immune stimulating effects of a new standardized Echinacea angustifolia root extract (Polinacea). Fitoterapia 2005; 76: 401-11.
- Woelkart K and Bauer R: The role of alkamides as an active principle of Echinacea. Planta Med 2007; 73: 615-23.
- Oka S, Yanagimoto S, Ikeda S, Gokoh M, Kishimoto S and Waku K: Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoyl phorbol-13-acetate-induced acute inflammation in mouse ear. J Biol Chem 2005; 280: 18488-97.
- Chicca A, Raduner S, Pellati F, Strompen T, Altmann KH and Schoop R: Synergistic immunopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts. Int Immunopharmacol 2009; 9: 850-8.
- Di Carlo G, Nuzzo I, Capasso R, Sanges MR, Galdiero E and Capasso F: Modulation of apoptosis in mice treated with Echinacea and St. John's wort. Pharmacol Res 2003; 48: 273-7.
- Di Carlo G, Nuzzo I and Capasso R: Modulation of apoptosis in mice treated with Echinacea and St. John’s Wort,’’ Pharmacological Ressearch 2003; 48(3): 273-277.
- Dong GC, Chuang PH, Forrest MD, Lin C and Chen HM: Immuno-suppressive effect of blocking the CD28 signaling pathway in T-cells by an active component of Echinacea found by a novel pharmaceutical screening method. J Med Chem 2006; 49: 1845-54.
- Chicca A, Adinolfi B, Martinotti E, Fogli S, Breschi MC and Pellati F: Cytotoxic effects of Echinacea root hexanic extracts on human cancer cell lines. J Ethnopharmacol 2007; 110: 148-53.
- Chicca A, Pellati F, Adinolfi B, Matthias A, Massarelli I and Benvenuti S: Cytotoxic activity of polyacetylenes and polyenes isolated from roots of Echinacea pallida. Br J Pharmacol 2008; 153: 879-85.
- Hayashi I, Ohotsuki M, Suzuki I and Watanabe T: Effects of oral administration of Echinacea purpurea (American herb) on the incidence of spontaneous leukemia caused by recombinant leukemia viruses in AKR/J mice. Nihon Rinsho Meneki Gakkai Kaishi 2001; 24: 10-20.
- Skaudickas D, Kondrotas AJ, Kevelaitis E and Venskutonis PR: The effect of Echinacea purpurea (L.) Moench extract on experimental prostate hyperplasia. Phytother Res 2009; 23: 1474-8.
- Bertoglio JC, Folatre I, Bombardelli E, Riva A, Morazzoni P and Ronchi M: Management of gastrointestinal mucositis due to cancer therapies in pediatric patients: results of a case series with SAMITAL(®).Future Oncol 2012; 8: 1481-6.
- Morazzoni P, Petrangolini G, Bombardelli E, Ronchi M, Cabri W and Riva A: SAMITAL®: a new botanical drug for the treatment of mucositis induced by oncological therapies. Future Oncol 2013; 9: 1717-25.
- Zhai Z, Haney D, Wu L, Solco A, Murphy PA and Wurtele ES: Alcohol extracts of Echinacea inhibit production of nitric oxide and tumor necrosis factor-alpha by macrophages in-vitro. Food Agric Immunol 2007; 18: 221-236.
- Bany J, Siwicki AK, Zdanowska D, Sokolnicka I, Skopińska-Rózewska E and Kowalczyk M: Echinacea purpurea stimulates cellular immunity and anti-bacterial defence independently of the strain of mice. Pol J Vet Sci 2003; 6: 3-5.
- Cech NB, Kandhi V, Davis JM, Hamilton A, Eads D and Laster SM: Echinacea and its alkylamides: effects on the influenza A-induced secretion of cytokines, chemokines, and PGE₂ from RAW 264.7 macrophage-like cells. Int Immunopharmacol 2010; 10: 1268-78.
- Senchina DS, Wu L, Flinn GN, Konopka del N, McCoy JA and Widrlechner MP: Year-and-a-half old, dried Echinacea roots retain cytokine-modulating capabilities in an in vitro human older adult model of influenza vaccination. Planta Med 2006; 72: 1207-15.
- Sharma M, Arnason JT, Burt A and Hudson JB: Echinacea extracts modulate the pattern of chemokine and cytokine secretion in rhinovirus-infected and uninfected epithelial cells. Phytother Res 2006; 20: 147-52.
- Sharma M, Schoop R and Hudson JB: The efficacy of Echinacea in a 3-D tissue model of human airway epithelium. Phytother Res. 2010; 24: 900-4.
- Speroni E, Govoni P, Guizzardi S, Renzulli C and Guerra MC: Anti-inflammatory and cicatrizing activity of Echinacea pallida root extract. J Ethnopharmacol 2002; 79: 265-72.
- Ghaemi A, Soleimanjahi H, Gill P, Arefian E, Soudi S and Hassan Z: Echinacea purpurea polysaccharide reduces the latency rate in herpes simplex virus type-1 infections. Intervirology 2009; 52: 29-34.
- Sharma M, Anderson SA, Schoop R and Hudson JB: Induction of multiple pro-inflammatory cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal extract. Antiviral Res 2009; 83: 165-70.
- Moltó J, Valle M, Miranda C, Cedeño S, Negredo E and Clotet B: Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients. Antimicrob Agents Chemother 2012; 56: 5328-31.
- Robinson WE: L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350). Antiviral Res 1998; 39: 101-11.
- Canlas J, Hudson JB, Sharma M and Nandan D: Echinacea and trypanasomatid parasite interactions: growth-inhibitory and anti-inflammatory effects of Echinacea. Pharm Biol 2010; 48: 1047-52.
- Roesler J, Steinmüller C, Kiderlen A, Emmendörffer A, Wagner H and Lohmann-Matthes ML: Application of purified polysaccharides from cell cultures of the plant Echinacea purpurea to mice mediates protection against systemic infections with Listeria monocytogenes and Candida albicans. Int J Immunopharmacol 1991; 13: 27-37.
- Cruz I, Cheetham JJ, Arnason JT, Yack JE and Smith ML: Alkamides from Echinacea disrupt the fungal cell wall-membrane complex. Phytomedicine 2014; 21: 435-42.
- Jawad M, Schoop R, Suter A, Klein P and Eccles R: Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med 2012; 2012 841315.
- Brinkeborn RM, Shah DV and Degenring FH: Echinaforce and other Echinacea fresh plant preparations in the treatment of the common cold. A randomized, placebo-controlled, double-blind clinical trial. Phytomedicine 1999; 6: 1-6.
- Goel V, Lovlin R, Barton R, Lyon MR, Bauer R and Lee TD: Efficacy of a standardized echinacea preparation (Echinilin) for the treatment of the common cold: a randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther 2004; 29: 75-83.
- Goel V, Lovlin R, Chang C, Slama JV, Barton R and Gahler R: A proprietary extract from the echinacea plant (Echinacea purpurea) enhances systemic immune response during a common cold. Phytother Res 2005; 19: 689-94.
- Rauš K, Pleschka S, Klein P, Schoop R and Fisher P: Effect of an Echinacea-Based Hot Drink Versus Oseltamivir in Influenza Treatment: A Randomized, Double-Blind, Double-Dummy, Multicenter, Noninferiority Clinical Trial. Curr Ther Res Clin Exp 2015; 77: 66-72.
- Yakoot M and Salem A: Efficacy and safety of a multiherbal formula with vitamin C and zinc (Immumax) in the management of the common cold. Int J Gen Med 2011; 4: 45-51.
- Minetti AM, Forti S, Tassone G, Torretta S and Pignataro L: Efficacy of complex herbal compound of Echinacea angustifolia (Imoviral® Junior) in recurrent upper respiratory tract infections during pediatric age: preliminary results. Minerva Pediatr 2011; 63: 177-82.
- Isbaniah F, Wiyono WH, Yunus F, Setiawati A, Totzke U and Verbruggen MA: Echinacea purpurea along with zinc, selenium and vitamin C to alleviate exacerbations of chronic obstructive pulmonary disease: results from a randomized controlled trial. J Clin Pharm Ther 2011; 36: 568-76.
- Taylor JA, Weber W, Standish L, Quinn H, Goesling J and McGann M: Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA 2003; 290: 2824-30.
- Yale SH and Liu K: Echinacea purpurea therapy for the treatment of the common cold: a randomized, double-blind, placebo-controlled clinical trial. Arch Intern Med 2004; 164: 1237-41.
- Grimm W and Müller HH: A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections. Am J Med 1999; 106: 138-43.
- O'Neil J, Hughes S, Lourie A and Zweifler J: Effects of echinacea on the frequency of upper respiratory tract symptoms: a randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 2008; 100: 384-8.
- Barrett B, Brown R, Rakel D, Mundt M, Bone K and Barlow S: Echinacea for treating the common cold: a randomized trial. Ann Intern Med 2010; 153: 769-77.
- Barrett BP, Brown RL, Locken K, Maberry R, Bobula JA and D'Alessio D: Treatment of the common cold with unrefined echinacea. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 939-46.
- Melchart D, Walther E, Linde K, Brandmaier R and Lersch C: Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial. Arch Fam Med 1998; 7: 541-5.
- Karsch-Völk M, Barrett B, Kiefer D, Bauer R, Ardjomand-Woelkart K and Linde K: Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev 2014; 2: CD000530.
- Rezaie A, Fazlara A, Haghi Karamolah M, Shahriari A, Najaf Zadeh H and Pashmforosh M: Effects of Echinacea purpurea on Hepatic and Renal Toxicity Induced by Diethylnitrosamine in Rats. Jundishapur J Nat Pharm Prod 2013; 8: 60-4.
- Hou CC, Huang CC and Shyur LF: Echinacea alkamides prevent lipopolysaccharide/D-galactosamine-induced acute hepatic injury through JNK pathway-mediated HO-1 expression. J Agric Food Chem 2011; 59: 11966-74.
- Smalinskiene A, Lesauskaite V, Ryselis S, Abdrakhmanov O, Kregzdyte R and Sadauskiene I: Assessment of the effect of Echinacea purpurea (L.) Moench on apoptotic and mitotic activity of liver cells during intoxication by cadmium. Ann N Y Acad Sci 2007; 1095: 574-84.
- Delorme D and Miller SC: Dietary consumption of Echinacea by mice afflicted with autoimmune (type I) diabetes: effect of consuming the herb on hemopoietic and immune cell dynamics. Autoimmunity 2005; 38: 453-61.
- Yotsawimonwat S, Rattanadechsakul J, Rattanadechsakul P and Okonogi S: Skin improvement and stability of Echinacea purpurea dermatological formulations. Int J Cosmet Sci 2010; 32: 340-6.
- Speroni E, Govoni P, Guizzardi S, Renzulli C and Guerra MC: An anti-inflammatory and cicatrizing activity of Echinacea pallida Nutt. root extract. J Ethnopharmacol 2002; 79: 265-72.
- Zhai Z, Haney DM, Wu L, Solco AK, Murphy PA and Wurtele ES: Alcohol extract of Echinacea pallida reverses stress-delayed wound healing in mice. Phytomedicine 2009; 16: 669-78.
- Hájos N, Holderith N, Németh B, Papp OI, Szabó GG and Zemankovics R: The effects of an Echinacea preparation on synaptic transmission and the firing properties of CA1 pyramidal cells in the hippocampus. Phytother Res 2012; 26: 354-62.
- Haller J, Hohmann J and Freund TF: The effect of Echinacea preparations in three laboratory tests of anxiety: comparison with chlordiazepoxide. Phytother Res 2010; 24: 1605-13.
- Haller J, Freund TF, Pelczer KG, Füredi J, Krecsak L and Zámbori J: The anxiolytic potential and psychotropic side effects of an echinacea preparation in laboratory animals and healthy volunteers. Phytother Res 2013; 27: 54-61.
- Woelkart K, Xu W, Pei Y, Makriyannis A, Picone RP and Bauer R: The endocannabinoid system as a target for alkamides from Echinacea angustifolia Planta Med 2005; 71: 701-5.
- Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J and Faller B: Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J Biol Chem 2006; 281: 14192-206.
- Skaudickas D, Kondrotas A and Baltrusaitis K: The effect of Echinacea purpurea extract on sexual glands of male rats. Medicina (Kaunas) 2004; 40: 1211-8.
- Ondrizek RR, Chan PJ, Patton WC and King A: Inhibition of human sperm motility by specific herbs used in alternative medicine. J Assist Reprod Genet 1999; 16: 87-91.
- Starvaggi Cucuzza L, Motta M, Accornero P and Baratta M: Effect of Echinacea augustifolia extract on cell viability and differentiation in mammary epithelial cells. Phytomedicine 2008; 15: 555-62.
- Hewitt NJ, Lecluyse EL and Ferguson SS: Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in-vitro – in-vivo Xenobiotica 2007; 37: 1196-224.
- Mrozikiewicz PM, Bogacz A, Karasiewicz M, Mikolajczak PL, Ozarowski M and Seremak-Mrozikiewicz A: The effect of standardized Echinacea purpurea extract on rat cytochrome P450 expression level. Phytomedicine 2010; 17: 830-3.
- Matthias A, Gillam EM, Penman KG, Matovic NJ, Bone KM and De Voss JJ: Cytochrome P450 enzyme-mediated degradation of Echinacea alkylamides in human liver microsomes. Chem Biol Interact 2005; 155: 62-70.
- Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK and Zaheer NA: The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in-vivo. Clin Pharmacol Ther 2004; 75: 89-100.
- Awortwe C, Manda VK, Avonto C, Khan SI, Khan IA and Walker LA: Echinacea purpurea up-regulates CYP1A2, CYP3A4 and MDR1 gene expression by activation of pregnane X receptor pathway. Xenobiotica 2015; 45: 218-29.
- Modarai M, Yang M, Suter A, Kortenkamp A and Heinrich M: Metabolomic profiling of liquid Echinacea medicinal products with in-vitro inhibitory effects on cytochrome P450 3A4 (CYP3A4). Planta Med 2010; 76: 378-85.
- Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB and Carrier J: In-vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004; 76: 428-40.
- Penzak SR, Robertson SM, Hunt JD, Chairez C, Malati CY and Alfaro RM: Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy 2010; 30: 797-805.
- Mahringer A, Ardjomand-Woelkart K, Bauer R, Fricker G and Efferth T: Alkamides from Echinacea angustifolia Interact with P-glycoprotein of primary brain capillary endothelial cells isolated from porcine brain blood vessels. Planta Med 2013; 79: 214-8.
- Romiti N, Pellati F, Nieri P, Benvenuti S, Adinolfi B and Chieli E. P-Glycoprotein inhibitory activity of lipophilic constituents of Echinacea pallida roots in a human proximal tubular cell line. Planta Med 2008; 74: 264-6.
- Hansen TS and Nilsen OG: Echinacea purpurea and P-glycoprotein drug transport in Caco-2 cells. Phytother Res 2009; 23: 86-91.
- Mohamed MF, Tseng T and Frye RF. Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity. Xenobiotica 2010; 40: 663-9.
- Matthias A, Blanchfield JT, Penman KG, Toth I, Lang CS and De Voss JJ: Permeability studies of alkylamides and caffeic acid conjugates from echinacea using a Caco-2 cell monolayer model. J Clin Pharm Ther 2004; 29:7-13.
- Mengs U, Clare CB and Poiley JA: Toxicity of Echinacea purpurea. Acute, subacute and genotoxicity studies. Arzneimittelforschung 1991; 41: 1076-81.
- Schneider S, Reichling J, Stintzing FC, Messerschmidt S, Meyer U and Schnitzler P: Anti-herpetic properties of hydroalcoholic extracts and pressed juice from Echinacea pallida. Planta Med 2010; 76: 265-72.
- Khaksary Mahabady M, Ranjbar R, Arzi A, Papahn AA and Najafzadeh H: A comparison study of effects of Echinacea extract and levamisole on the phenytoin-induced cleft palate in mice. Regul Toxicol Pharmacol 2006; 46: 163-6.
- Hu X, Chen Z, Mao X and Tang S: Effects of phenytoin and Echinacea purpurea extract on proliferation and apoptosis of mouse embryonic palatal mesenchymal cells. J Cell Biochem 2011; 112: 1311-7.
- Huntley AL, Thompson Coon J and Ernst E: The safety of herbal medicinal products derived from Echinacea species: a systematic review. Drug Saf 2005; 28: 387-400.
- Mullins RJ: Echinacea-associated anaphylaxis. Med J Aust 1998; 168: 170-1.
- Hill LL, Foote JC, Erickson BD, Cerniglia CE and Denny GS: Echinacea purpurea supplementation stimulates select groups of human gastrointestinal tract microbiota. J Clin Pharm Ther 2006; 31: 599-604.
- Sparreboom A, Cox MC, Acharya MR and Figg WD: Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004; 22: 2489-503.
- Cavaliere C, Rea P, Lynch ME and Blumenthal M: Herbal Supplement Sales Rise in All Channels in 2009. HerbalGram 2010; 86: 62-5.
How to cite this article:
Ganjuri M, Darakhshan S and Taghizad F: A review on pharmacological and therapeutic properties of Echinacea. Int J Pharmacognosy 2016; 3(10): 410-36. doi link: http://dx.doi.org/10.13040/IJPSR.0975-8232.IJP.3(10).410-36.
This Journal licensed under a Creative Commons Attribution-Non-commercial-Share Alike 3.0 Unported License.
M. Ganjuri, S. Darakhshan * and F. Taghizad
Department of Biology, Faculty of Science, Razi University, Kermanshah, Iran.
20 August 2016
11 October 2016
25 October 2016
31 October 2016